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PROFILING CELL SURFACE SIALYLATION AND
DESIALYLATION DYNAMICS OF IMMUNE CELLS
DAN WANG

ABSTRACT
Sialic acids (SAs) are a diverse family of naturally occurring 2-keto-3-deoxynononic acids that are involved in a wide range of biological processes, including early
fetal development, cellular recognition, and utilization by microbes. While it is clear that
cell surface SAs are highly involved in the immune system, the sialylation status of
individual immune cells and functions are still unknown. In this study, I combined the
newly developed LC-MS/MS methods with flow cytometry and confocal microscopy to
systematically study the sialylation and desialylation dynamics of macrophages at different
conditions.
First, I developed an accurate LC-MS/MS method to quantify free SA in human
plasma with isotope-labeled standard calibration and 3,4-diaminotoluene derivatization.
This method is capable to distinguish SA analogus in complex biological samples, which
paves the path for dynamic SAs research. Menwhile, another LC-MS/MS method with
direct SAs quantification was developed for high throughtput analysis. This method does
not require complicated sample preparation and can quantify SA at 2 ng/mL.
Next, I performed globally profiling of sialylation status of Raw 264.7 macrophages
by flow cytometry, confocal microscopy, and LC-MS/MS. Both flow cytometry and
confocal microscopy showed the predominat of α-2,3 linked SAs on the cell surface, and
iv

increase of α-2,6 linked SAs after atorvastatin treatment. Moreover, LC-MS/MS showed
total SA increased 3 times upon treatment. Further experiment indicated the correlation of
α-2,6 linked SAs with cell apoptosis.
Finally, I systematically examined the sialylation and desialylation profiles of THP1 monocytes after differentiation and polarization. Both α-2,3 and α-2,6 linked SAs on the
cell surface were decreased during diffrentiation, which was in accordance with the
increased free SA in the medium and elevated activity of NEU1 sialidase. Meanwhile, the
increase of SA expression during differentiation was evidenced by siaoglycoconjugates
inside the cells and total SA in the cell lysate.
Overall, the combined approach has bee successfully applied to profile SAs in the
cell culture system. LC-MS/MS can accurately quantify SA in a high throughtput fashion.
The SA linkages can be distinguished by flow cytometry and confocal microscopy with
specific lectin labelings. The SA levels and linkages provide markers of cells at different
status.

v
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CHAPTER I
INTRODUCTION TO SIALIC ACID

1.1

Sialic acid
The surfaces of all vertebrate cells in nature comprise a variety of glycoconjugates

including glycoproteins, proteoglycans and glycolipids forming the cellular glycocalyx
layer, which was original revealed by electromicroscopy in 1967 [1, 2]. Sialic acids (SAs)
at the “outermost” location of these glycoconjugates are known as the “functional
ornament” of the glycocalyx and provide extreme structural and functional diversities
(Figure 1). The two major SA core structures are 2-keto-3-deoxynononic-acid (KDN) and
neuraminic acid (Neu) sharing nine carbons and differing at the C5-position (Figure 2).
The variety of substituents on carbon 4, 5, 7, 8 and 9 generate a diverse family of more
than 50 structurally distinct molecules, which can be attached to underlying sugars
commonly via α-2,3 or α-2,6 linkage to galactose (Gal), via α-2,6 linkage to N-

acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), or via α-2,8 linkage to
another SA [1, 3-5]. N-acetylneuraminic acid (Neu5Ac) is the most frequent form,

1

followed by N-glycolylneuraminic acid (Neu5Gc) and O-acetylated derivatives, mostly Nacetyl-9-O-acetylneuraminic acid (Neu5,9Ac2). Among mammals, humans are a known
exception in their lack of Neu5Gc, due to an inactivation mutation in a hydroxylase, which
modifies CMP-Neu5Ac to CMP-Neu5Gc [6].

2

Figure 1:

The complexity of SA layer on the cell surface. Adapted from reference 4

with permission from Mary Ann Liebert, Inc.

3

Figure 2:

Diversity of SA structures and linkages.

4

Given their remarkable diversities in structures, glycosidic linkages, and underlying
glycan chains, as well as their exposed location, it is not surprising that SAs can mediate
and modulate a wide variety of physiological and pathological processes, such as
immunological process, hormonal response, signal transduction, tumor progression, cell
adhesion and protection [7-10]. Firstly, by virtue of the negative charge and hydrophilicity,
SAs act as biological masks, which are anti-recognition agents by shielding recognition
sites such as sub-terminal galactose residues, antigenic proteins and other macromolecules
of cell membranes including receptor molecules. Secondly, SAs function in the opposite
way by being biological recognition sites for a great variety of proteins, which are
collectively called lectins. Angata et al. proposed to group these glycan recognition
proteins into three categories: vertebrate pathogen lectins, vertebrate endogenous lectins,
and lectins from other sources such as plants, protostomes, etc. [3] Vertebrate pathogen
lectins generally show more specificity on SA structures compared to vertebrate
endogenous lectins. For example, most influenza viruses A that spread among birds

preferentially recognize SA with α-2,3 linkage to underlying sugar. Humans are resistant

to infection at least partly by such virus because we instead display α-2,6 linked SA on the
epithelium of upper airways [11, 12]. Another example is the lectins, named adhesions in
bacteria, expressed by E. coli K99 strain shows high specificity towards
Neu5Gcα2,3Galβ1,4Glc structure on glycolipids, which is abundantly expressed in the
gastrointestinal tract of piglets [13]. Plant lectins are traditionally powerful tool to study
glycan structures. Their high specificity is able to distinguish isomeric glycans with
identical sugar compositions. For example, Sambucus nigra agglutinin (SNA) binds in a
highly selective fashion to SA linked to either Gal or GalNAc via α-2,6 linkage. In contrast
5

to SNA, the family of lectins from Maackia amurensis seeds (MAA) recognize α2,3-linked
SA [14].
Vertebrate endogenous lectins are usually found in immune system. The most
studied lectins include factor H, selectins, and siglecs. Factor H is one of the first
discovered vertebrate lectins. Factor H is a “self” identification marker that binds to cell
surface SAs to protect cells from the alternative complement pathway [15, 16]. Selectins,
a family of three type-I cell surface glycoproteins including E-, L- and P-selectin,
participate in many cell-cell interactions in immunity, haemostasis and inflammation [17].
Leukocyte (L)-selectin, which is constitutively expressed on many types of leukocytes, can
recognize the sialylated ligands on endothelial venules and then facilitate homing of the
cells into lymph nodes. Moreover, independent evidence shows leukocyte adhesion to
activated endothelial cells is also mediated by endothelial (E)-selectin which recognize
SAs on the leukocytes [18]. However, E-selectin is not constitutively expressed, and
requires transcriptional induction by various inflammatory stimuli. Platelet (P)-selectin,

which is stored in α-granules of platelets and Weibel-Palade bodies of endothelial cells,
can rapidly mobilize to the cell surface in response to various stimuli, again mediating
adhesion to SA-containing ligands on leukocytes [17]. Siglecs are a family of SA-binding
immunoglobulin-like receptors that participate in the discrimination of “self” and “nonself” and regulate the functions of cells in the innate and adaptive immune systems through
recognition of their glycan ligands [19-21]. To date 14 siglecs have been identified in
humans, and show highly restricted expression in immune system and the differential
expression in various immune cells, such as sialoadhesin in macrophages, CD22 in B cells,
MAG in oligodendrocytes and schwann cells, CD33 in macrophages and granulocytes, etc.
6

Sialoadhesion, CD22, MAG and Siglec-15 are conserved across mammals, while the group
of CD33-related Siglecs show a great diversity among the species. Most Siglecs are
typically bound to sialylated glycans on the same cell surface (cis interaction). However,
another cell surface or a soluble ligand with a high enough density of sialylated ligands can
compete out the cis ligand and cause engagement [19]. This can provide insight why SAs
are found in so many bacterial and viruses, such as group B streptococcus, Neisseria
meningitides, HIV, porcine reproductive and respiratory syndrome virus, etc. [20-23] On
one hand, SAs could provide the pathogen with suppression of the alternative pathway via
Factor H, hijack host Siglecs, and get into the host cells. On the other hand, pathogens also
use host sialylated structures as ligands for binding and recognition. For example, influenza
virus binds to hosts SAs via hemagglutinin, and then cleave the SAs on the same receptors
with sialidase to achieve successful infection [24].

7

Figure 3:

Multifarious roles of SAs in immunity. (A) Structure of Neu5Ac, the most

common SA in mammals. (B) The high density of SAs on cell surface imparts negative
charge and hydrophilicity to cells. (C) Factor H binds cell surface SAs, protecting cells
from the alternative complement pathway. (D) Selectins on endothelia and leukocytes
initiate leukocytes rolling on endothelial surfaces. (E) Siglecs on immune cells detect
sialylated ligands and can inhibit immune cell activation. (F) Host SAs are frequently
exploited as attachment sites for pathogens. (G) Microbial sialidases can help pathogens to
expose underlying glycan-binding sites, to avoid sialylated decoys. (H) Endogenous
sialidases can modulate immune cell functions by modulating receptor clustering, possibly
8

by exposing underlying Gal residues and facilitating galectin (Gal receptor) mediated
cross-linking of surface molecules. (I) Microbial mimicry of host SAs allows manipulation
of host immune response by engaging inhibitory Siglecs, inhibiting complement via factor
H binding, and reducing the opportunity of the host to form antibodies. (J) Microbial
synthesis of SA-like molecules, such as legionaminic acid and pseudaminic acid stabilizes
fimbriae. Adapted from reference 23 with permission from John Wiley and Sons.

9

1.2

Sialylation
In general, SAs are synthesized in the cytosol and then presented at the terminal of

glycoproteins and glycolipids anchored on the cell surface (Figure 4) [25]. The biosynthesis
of SAs starts with UDP-GlcNAc, which is the key compound of the whole amino sugar
metabolism. This nucleotide sugar is formed by the hexosamine pathway, which splits off
from glycolysis at the stage of fructose 6-phosphate. A minor portion of UDP-GlcNAc
participates into SAs synthesis pathway. The formation of Neu5Ac from UDP-GlcNAc is
carried out in the cytosol, and requires three enzymes with four enzymatic steps. NAcetylmannosamine (ManNAc) is a dedicated metabolic precursor for the Neu5Ac
synthesis with no other roles in cells. The first two steps of the enzymatic reactions are
catalyzed by a bifunctional enzyme called UDP-GlcNAc 2-epimerase/ManNAc kinase
(GNE) with both hydrolyzing UDP-GlcNAc 2-epimerase and ManNAc kinase activities.
The epimerase function of the GNE converts UDP-GlcNAc to ManNAc with removal of
the UDP moiety and epimerization of the GlcNAc. The kinase function of GNE then
phosphorylates ManNAc to form ManNAc-6-P. The Neu5Ac-9-P synthase (NANS) uses
ManNAc-6-P to catalyzes an aldol addition with phosphoenolpyruvate (PEP) for the
formation of Neu5Ac-9-P. This enzymatic reaction is followed by the release of the 9phosphate group from Neu5Ac-9-P by Neu5Ac-9-P phosphatase (NANP). The pathway
then moves from cytosol to nucleus where the de novo synthesized Neu5Ac is converted
into CMP-Neu5Ac by the CMP-Neu5Ac synthetase. Lastly, the nucleotide sugar is
transported to the Golgi apparatus by the CMP-SA transporter and is served as substrate
for different sialyltransferases to install α-2,3, α-2,6, or α-2,8 linked sialosides into
glycoproteins or glycolipids [26-28]. However, the biosynthesis of sialyl glycoconjugates
10

is complicated by the additional modifications on SA either before or after the formation
of sialyl linkages in the Golgi, such as the formation of non-human Neu5Gc in animals and
O-acetlylation in different hydroxyl groups [29-30].
Sialyltransferases are enzymes that directly control the cell surface sialylation
patterns, which are typically insensitive to changes in metabolic flux because the Golgi
concentration of CMP-Neu5Ac exceeds the Km for sialyltransferases [31]. Consequently,
sialyltransferes are the targets that cells use to regulate their sialylation status in response
to variable physiological and pathological stimuli. Twenty distinct sialyltransferases have
been identified in both human and murine genomes, and all of them are type II
transmembrane glycoproteins that predominantly reside in the trans-Golgi compartment
[32]. Based on the type of linkage formation and nature of sugar acceptor, these enzymes
can be categorized into four distinct families: ST3Gal family, ST6Gal family, ST6GalNAc
family, and ST8SA family [27, 33-35]. All the described ST3Gal family transfer Neu5Ac
residues in α-2,3 linkage to terminal Gal residues found in glycoproteins and glycolipids.
In this family, the ST3Gal I and II subfamilies use exclusively the type 3 oligosaccharide
structure Galβ1,3GalNAc-R, whereas the ST3Gal III, IV, V, and VI use the oligosaccharide
isomers Galβ1,3/4GlcNAc-R. The enzymes of ST6Gal family comprise only two
subfamilies, ST6Gal I and II, which both use the Galβ1,4GlcNAc-R as the acceptor
substrate. ST6GalNAc family catalyze the transfer of Neu5Ac residues in α-2,6 linkage to
the GalNAc residues found in O-glycosylproteins (ST6GalNAc I, II, and IV) and
glycolipids (ST6GalNAc III, V, and VI). The six members of ST8SA family mediate the
transfer of Neu5Ac residues in α-2,8 linkage to other Neu5Ac residues found in
11

glycoproteins and glycolipids, among which ST8Sia II and ST8Sia IV are
polysialyltransferases.

12

Figure 4:

Overview of mammalian SAs metabolism. Adapted from reference 25 with

permission from Oxford University Press.
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1.3

Desialylation
Sialidases are a family of exo-glycosidases that catalyze the hydrolytic cleavage of

non-reducing SA residues linked to the glycan structures of glycoproteins, glycolipids, and
oligosaccharides. They are widely distributed in nature, from virus and microorganisms to
vertebrates, but absent in plants, insects, and yeast [36, 37]. Four types of mammalian
sialidases have been identified and characterized to date, and the classification is based on
their subcellular localization, namely the intra lysosomal sialidase (NEU1), the cytosolic
sialidase (NEU2), the plasma membrane-associated sialidase (NEU3), and the lysosomal
or mitochondrial membrane-associated sialidase (NEU4) (Table I) [38]. NEU1 is
ubiquitously but differentially expressed in tissues and cells, and has been purified from
many sources, such as placenta, mammary gland, brain, and liver [38, 39]. In human
tissues, NEU1 generally shows strongest expression, 10-20 times higher than those of
NEU3 and NEU4, whereas NEU2 expression is extremely low and only reported in a range
of tissues such as placenta and testis [40, 41]. NEU3 shows the highest expression in
adrenal gland, skeletal muscle, heart, testis, and thymus [42]. NEU4 has the highest
expression in brain, skeletal muscle, heart, placenta, and liver [43].
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TABLE I: General properties of four mammalian sialidases.
NEU1

NEU2

Major
subcellular
localization

Lysosomes

Cytosol

Good substrates

Oligosaccharides,
Glycopeptides

Optimal pH

4.4-4.6
Exocytosis;

Immune function;

Elastic fiber assembly;
Carcinogenesis
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NEU4

Plasma membranes

Lysosomes,
Mitochondria and ER

Oligosaccharides,
Glycoproteins,
Gangliosides

Gangliosides

Oligosaccharides,
Glycoproteins,
Gangliosides

6.0-6.5

4.5-4.7

4.5-4.7

Myoblast
differentiation

Neuronal and muscle
differentiation;
Apoptosis;

Neuronal differentiation;
Apoptosis

Degradation in lysosomes;
Proposed major
functions

NEU3

1.3.1

NEU1
Studies carried out so far have demonstrated the distinct target substrates and

biological functions among all these four mammalian sialidases [44]. NEU1 is the only
sialidase that functions in a multienzyme complex containing at least two other hydrolases
including the glycosidase β-galactosidase (β-GAL) and the serine carboxypeptidase
protective protein/cathepsin A (PPCA). In acidic condition, such as lysosomal
environment, PPCA can promote the formation of NEU1 oligomers, which are catalytically
active against sialylated oligosaccharides and glycoproteins with a preference for α-2,3 and
α-2,6 sialyl linkages [45, 46]. The role of β-GAL in the multienzyme complex is not so
clear, but it may provide a means of regulation of their activities, or may enhance their
stability. NEU1 is crucial for the lysosomal catabolism of sialylated glycoconjugates. The
defective or deficient enzyme activity is associated with two neurodegenerative lysosomal
storage disorders, sialidosis and galactosialidosis (GS). Sialidosis is caused by structural
lesions in the NEU1 gene, while GS is a combined deficiency of NEU1 and β-GAL caused
by the absence of functional PPCA [47, 48]. Except the well-studied lysosomal catabolic
function, the emerging studies mainly based on sialidase deficient animal models have
revealed new roles of NEU1 in diverse cellular regulatory pathways including exocytosis,
immune function, elastic fiber assembly, and carcinogenesis.
1.3.1.1 Exocytosis
NEU1 negatively regulates lysosomal exocytosis, a cellular process for the
recruitment of lysosome to the plasma membrane, resulting in an increase in extracellular
proteolytic activity [49, 50]. Neu1 (-/-) mice showed enhanced secretion of lysosomal
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proteases and glycosidases and an increased presence of heavily sialylated lysosome
associated membrane protein 1 (LAMP-1), which was identified as a target substrate of
NEU1. In contrast, silencing of LAMP-1 expression in the cells leads to normalization of
the LAMP-1 distribution and reduction in lysosomal exocytosis [49]. Furthermore, the
increased lysosomal exocytosis in Neu1 (-/-) mice was linked to reduced endolymphatic
potential, dysfunction of transduction in sensory hair cells and hearing loss that were also
observed in sialidosis patients [51]. Interestingly, a recent published study showed sarcoma
cells gained invasive and drug-resistant abilities by inducing lysosomal exocytosis [52].
Down-regulation of NEU1 and accumulation of oversialylated LAMP-1, tumor cells
exacerbate lysosomal exocytosis of soluble hydrolases and exosomes. This facilitates
matrix invasion and propagation of invasive signals, and purging of lysosomotropic
chemotherapeutics. These malignant traits were reversed by inhibiting lysosomal
exocytosis in Neu1 haploinsufficient mice.
1.3.1.2 Immune function
Cell surface SAs are implicated as potential modulator of immune cell interaction.
It has been known for decades that sialidase treatment could substantially enhance the
capacity of resting B cells to stimulate the proliferation of allogeneic and antigen specific,
syngeneic T cells [53, 54]. It is suggested that sialidase treatment may be an analogue for
an authentic step in B cell activation, which shows specific loss of α-2,6 linked SA in highly
activated B cells. Moreover, different studies have shown the NEU1 on the surface of
activated T cells is essential to general cell surface desialylation and to production of
cytokines such as inerleukin 4 (IL-4) and interferon γ (IFN-γ) [55, 56]. Further, the
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presenting of NEU1 is required for T cells interaction with antigen presenting cells and
converting the group specific component protein into a factor necessary for the
inflammation-primed activation of macrophages [57, 58].
Our study and several other studies have demonstrated during the differentiation of
circulating blood monocytes and monocytic cell lines into macrophages, the NEU1 activity
is dramatically increased, while NEU2, NEU3, and NEU4 are unchanged or even reduced
[59-61]. In this process, NEU1 and its activator PPCA were first targeted to the lysosome
and then sorted to the LAMP-2 negative and MHC II positive vesicles, which later merged
with the plasma membrane [60]. In line with this finding, the genetic approach showed
macropahges and immature dendritic cells from NEU1-deficient mice presenting increased
sialylation of the cell surface and compromised ability to phagocytosis [62]. As expected,
this phenotype was reversed by the exogenous NEU1 treatment, which can affect the
transduction of signals from the Fc receptors for immunoglobulin G via desialylation.
Another NEU1 regulated immune receptor is Toll-like receptors (TLR) that play key roles
in activating immune response during infection [63, 64]. Ligand binding to TLR-2, -3, and
-4 rapidly induces NEU1 activity that promotes intracellular signaling [63, 64]. This
activity is speculated due to the removing of SA from TLR by NEU1. Later study reveals
a broad repression of TLR function by Siglecs and a sialidase-mediated de-repression that
allows positive feedback of TLR activation during infection [65].
1.3.1.3 Elastic fiber assemble
The elastin-binding protein (EBP), identical to a spliced variant of β-GAL, forms a
cell surface elastin receptor with PPCA and NEU1. During the formation of elastic fibers,
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the EBP initially plays the role of intracellular chaperone for hydrophobic and nonglycosylated tropoelastin, protecting it from premature self-aggregation and degradation
by elastases, and facilitating its extracellular deposition on the microfibrillar scaffold [66,
67]. The cell surface-residing NEU1, which is presumably activated by the binding of EBP
tropoelastin complex or free SA generated from undetermined substrates [68], catalyzes
the removal of the terminal SA from carbohydrate chains of microfibrillar protein, forming
the structural scaffold of new elastic fiber, unmasking their penultimate galactose. The
exposed Gal then interacts with the galactolectin domain of the EBP, thereby inducing the
release of transported tropoelastin molecules and facilitating their subsequent assembly
into elastic fiber. Further studies with NEU1 deficient fibroblasts from sialidosis and GS
patients showed significantly less insoluble elastin as compared to control fibroblasts, but
had increased levels of soluble tropoelastin [66, 69]. This phenotype was reversed by the
addition of exogenous sialidase in the medium.
1.3.1.4 Carcinogenesis
Altered sialylation of tumor cell surface glycoconjugates has been described to be
highly associated with the metastatic phenotype of cancers. In particularly, decreasing
NEU1 expression is one of the characteristic features for multiple cancers, while with an
inverse correlation with metastatic ability [44, 70-72]. The level of NEU1 activity and
expression in different clones of transformed rat fibroblast 3Y1 cells and mouse
adenocarcinoma colon CT26 cells inversely correlated with their metastatic potential [73,
74]. Those transformed with v-fos had lower sialidase activity and higher metastatic
potential [73]. Further study from the same group demonstrated that overexpression of
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NEU1 in mouse B16 melanoma cells reversed their metastatic capacity as detected by the
suppression of the pulmonary metastasis in mice, invasiveness in collagen gels, and
motility on colloidal gold-coated glass plates [75]. Another work showed that NEU1
overexpression in colon cancer HT-29 cells significantly reduced their liver metastasis
potential in mice as well as migration, invasion, and adhesion properties in vitro, whereas
NEU1 silencing caused the opposite effect [76]. One of the target molecules of NEU1 has
been indentified to be laminin receptor, integrin β4, which undergoes desialylation and
decreased phosphorylation followed by attenuation of the focal adhesion kinases and
extracellular signal regulated kinase 1/2 (ERK 1/2) pathway, and downregulation of matrix
metalloproteinase-7 [76]. Interestingly, a microRNA, miR-125b, targeting eight transcripts
including NEU1 as metastatic suppressor, was found to promote growth of prostate cancers
in both intact and castrated male nude mice by down-regulating pro-apoptotic and tumor
suppressor genes [77]. Although many experiments do not identify the molecular
mechanism of the observed changes in metastatic capacity, they implicate NEU1 as a
negative regulator of malignant properties of cancer cells.
However, NEU1 does not always act as a cancer suppressor. A recent study found
that NEU1 was expressed in a higher level in ovarian cancer tissues than that in adjacent
normal tissues [78]. The inhibition of NEU1 with siRNA can effectively prevent the
proliferation, apoptosis, and invasion of human ovarian cancer cells, which was speculated
by targeting lysosome and oxidative phosphorylation signaling pathway [78]. Moreover,
in another proposed signaling paradigm, NEU1 was activated by an epidermal growth
factor receptor (EGFR)-induced G protein coupled receptor signaling process and
metalloproteinase-9 activation. This tripartite complex of G protein coupled receptor,
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MMP-9, and NEU1 forms an alliance with EGFR tethered at the ectodomain of the receptor
on the cell surface. Active NEU1 in the complex with EGFR hydrolyzes α-2,3 SA residues
on the receptors, enabling removal of steric hindrance of receptor association and allowing
subsequent dimerization, activation, and cellular signaling [79-81]. Subsequently,
therapeutic inhibiting of NEU1 with oseltamivir phosphate at the EGFR level disabled the
intrinsic signaling platform for cancer cell survival in human pancreatic cancer with
acquired chemoresistance [80, 81].
1.3.2

NEU2
NEU2 is the first example of a mammalian sialidase that cDNA cloning is achieved

based on the peptide sequence of the protein purified from rat skeletal muscle, where it
shows predominant expression [82]. Overexpression of human NEU2 homologue in E. coli
and the purification of the enzyme to homogeneity permit its detailed kinetic
characterization [83]. The highest catalytic activity and affinity are exhibited on α-2,3
linkage presenting in different sialoconjugates (gangliosides, glycoproteins, sialyl-lactose),
whereas the α-2,8 linkage in colominic acid and the α-2,6 linkage carried by α-2,6
sialyllactose are resistant to hydrolysis. The enzyme exhibits the highest activity on
gangliosides (GM3, GD1a, GD1b, GT1b, and α2, 3-sialylparagloboside) in their micellar
(vesicular in the case of GM3) supramolecular organization. Remarkably, GM1 and GM2
are recognized only as monomers with Km values as low as 10 nM, while micellar-form
monosialoganglioside GM2 and GM1 are not affected by NEU2.
Because of its almost exclusive expression in musculoskeletal tissues, the main
stream of NEU2 study is focused on the involvement in myoblast differentiation. The
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initial in vitro evidence was obtained from rat L6 myogenic cells [84]. In this regard, an
increased NEU2 gene transcription in L6 myoblasts appeared to be dependent on the
presence in the promoter region of two pairs of E-box sequence, which were known binding
sites for muscle-specific transcription factors involved in differentiation. Subsequently, a
similar transcriptional NEU2 upregulation was observed during differentiation of murine
C2C12 myoblasts [85]. NEU2 overexpressing clones showed decrement of cell
proliferation while enhanced spontaneous myoblast differentiation, which was evidenced
by the formation of myogenin-positive myotubes and a significant decrease in the nuclear
levels of cyclin D1 protein. The possible involvement of NEU2 in muscle regeneration in
vivo has been suggested in the dysferlin-deficient mouse model [86]. In this mouse model
for human dysferlinopathy the down-regulation of the NEU2 gene was associated with
impairment of muscle regeneration. These results provide evidences that NEU2
upregulation constitutes an important event to trigger in vitro myoblast differentiation. In
addition, NEU2 has been suggested to drive insulin-like growth factor 1-induced
hypertrophy of myoblasts [87]. In this signal pathway, the activation of the
phosphatidylinositol-3-kinase/serine-threonine protein kinase AKT1/mammalian target of
rapamycin pathway leaded to an increase of NEU2 level. This upregulation could be
obtained by using a constitutively activated form of AKT1, whereas transfection of a
kinase-inactive mutant of AKT1 inhibited myotube formation and causes NEU2 downregulation. Furthermore, the enzymatic activity of NEU2 is inversely regulated during in
vitro myoblast hypertrophy and atrophy [88]. As expected, hypertrophy was found to be
coupled to high levels of NEU2, whereas atrophy was characterized by a down-regulation
of the enzyme. However, it is still uncertain how NEU2 actually functions in human tissues
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and cells due to the extremely low expression. The biological and phylogenic significance
of marked decrease in NEU2 expression in the human tissues thus remains to be elucidated.
1.3.3

NEU3
NEU3 is membrane-associated sialidase that ubiquitously expressed in various of

animal species [38, 42]. It possesses specific activity for gangliosides, including GD3,
GD1a, GD1b and GM3; whereas sialyllactose, 4MU-NeuAc, GM1 and GM2 are poor
substrates, and it has no activity against sialylated glycoproteins such as fetuin, transferrin
and orosomucoid [89, 90]. Interestingly, the mouse NEU3, but not NUE2, seems to remove
even stable SA of GM1 and GM2 in the presence of GM2 activator protein [91]. Moreover,
the activity of sialidase NEU3 is exerted also on gangliosides exposed on the extracellular
leaflet of the plasma membrane of adjacent cells by cell-cell interaction [92]. The puzzling
mechanism of NEU3 anchorage to the membrane was solved by studying the
overexpressed mouse NEU3 in HeLa and COS-7 cells [93]. NEU3 behaves as a
peripherally associated membrane protein, presenting in both the plasma membrane and
the membranous structures corresponding to the recycling endosomal compartment, from
which it can be released by treatment with carbonate.
1.3.3.1 Regulation in membrane microdomains
NEU3 has been suggested to play essential roles in regulation of cell surface
functions because of its major localization in the plasma membrane and strict substrate
preference for gangliosides involved in signal transduction. NEU3 is located in rafts of
neuroblastoma cells and in caveolae of HeLa cells, closely associated with caveolin-1,
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probably through the caveolin-binding region [94, 95]. In caveolae, NEU3 has been
proposed to control platelet-derived growth factor (PDGF)-induced Src mitogenic
signaling and DNA synthesis by modification of GM1 levels at cell surfaces [96].
Caveolin-enriched membrane microdomains regulate the association of Src family protein
tyrosine kinases with PDGF receptor, which represents a pivotal site for kinase activation
and cell cycle progression. A member of the transmembrane adaptor protein family,
phosphoprotein associated with glycosphingolipid-enriched microdomains, induces NEU3
sialidase activity, leading to GM1 accumulations and PDGF receptor exclusion from
caveolae. The biological action of NEU3 is exerted through its activity on gangliosides,
which are essential structural and functional components of membrane microdomains.
Moreover, NEU3 is also found in tetraspanin-enriched microdomains (TERMs) [96].
Tetraspanins

are

a

family

of

membrane

proteins

involved

in

membrane

compartmentalization dynamics. Overexpression of NEU3 in HB2 mammary epithelial
cells affected the stability of CD82-containing TERMs, which showed the decreased
association with CD151, but enhanced association with EGFR. These results have
demonstrated the relevance of gangliosides, as NEU3 substrates, in maintaining the
integrity and functionality of CD82-enriched microdomains and suggested a role of NEU3
as possible physiological regulator of these membrane structures.
1.3.3.2 Promotion cell differentiation
The possibly important role of NEU3 in the proliferation control and differentiation
in neuronal cell system was revealed several years before the cloning of its cDNA [97].
The direct participation of NEU3 in neuronal cell differentiation was further proved by the
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stable transfection of the sialidase in Neuro2a cells, which showed the accelerating neurite
arborization following 5-bromodeoxyuridine treatment [98]. Recent studies provide
important details on the role played by NEU3 in axonal growth and regeneration via
regulation of GM1 level [99, 100]. GM1 has been shown to promote axon growth and
regeneration in vitro and in vivo. In contrast, the polysialylated gangliosides, GD1a and
GT1b, have been shown to act as receptors for myelin-associated inhibitors [101].
Application of exogenous sialidase that cleaves SA residues from polysialylated
gangliosides to generate monosialylated GM1 has been shown to relieve myelin-dependent
neuronal outgrowth inhibition as well as promote axon regeneration and functional
recovery in rats that have been subjected to spinal cord injury [100, 102]. Moreover, NEU3
asymmetrically accumulating at the tip of one neurite of the unpolarized rat neuron can
induce actin instability, thus triggers the polarization of neurons [103]. Suppressing the
enzymatic activity blocks axonal generation, whereas stimulating it accelerates the
formation of a single (not several) axon [103]. Underlying molecular mechanism indicates
NEU3 induces axon specification by enhancing TrkA activity locally, which triggers
phosphatidylinositol-3-kinase- and Rac1-dependent inhibition of RhoA signaling and the
consequent actin depolymerization in one neurite only.
NEU3 also plays a key role in skeletal muscle differentiation by strictly modulating
the ganglioside content, with special regard to GM3 [104-106]. Induced down-regulation
of NEU3 in murine skeletal muscle cells C2C12 myoblasts, even when partial, totally
inhibits their capability to differentiate by increasing the GM3 level above a critical point,
consequently leading to EGFR inhibition and ultimately down-regulation, and a higher
responsiveness of myoblasts to the apoptotic stimuli [104]. Conversely, the over expression
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of NEU3 affects the EGF signaling pathway in an opposite direction, which promoting cell
proliferation and delaying the beginning of the differentiation [105-106]. Regarding this
point, NEU3 is proposed as a cancer marker, because of its up-regulation has been found
to promote the suppression of cell apoptosis in human cancers by a mechanism dependent
on the depletion of gangliosides and subsequent over-activation of mitogenic receptor [71,
107-109].
1.3.4

NEU4
Human NEU4 is present in two isoforms, long (NEU4L) and short (NEU4S), which

are different in the presence or absence of 12 amino acids at the N-terminal, and the
subcellular location with NEU4L showing a mitochondrial localization and NEU4S in
association with endoplasmic reticulum (ER) [110, 111]. The isoforms are differentially
expressed in a tissue-specific manner. The brain, muscle and kidney contain both, whereas
the liver and colon possess predominantly the short form [110]. Although both isoforms
possess

broad

substrate

specificity

from

glycoproteins

to

gangliosides

and

oligosaccharides, they show reduced activity towards substrates containing a-2,6 linked
SA and branched Fuc residues [43, 112]. Interestingly, the mitochondrial localization of
NEU4L suggests that the protein could be involved in the pathways of mitochondrial
apoptosis through the regulation of the level of apoptogenic ganglioside GD3 within the
organelle [113, 114]. Mouse NEU4 also has two isoforms derived from alternative splicing,
designated NEU4a and NEU4b. However, the mouse Neu4 gene is expressed dominantly
in the brain, and only very low levels in other tissues [115]. The expression level of mouse
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gene increases 3-14 days after birth suggesting a role for brain development, presumably
through digestion of polysialic acids on surfaces of neuronal cell [116].
In addition to the mitochondria and ER membrane localization, NEU4 has also been
found in the lysosome lumen. In contrast to NEU1, NEU4 is targeted to lysosomes by the
Man 6-phosphate receptor and does not require association with other proteins for
enzymatic activity. Expression of NEU4 in the cells of sialidosis and galactosialidosis
patients resulted in clearance of storage materials from lysosomes, and this rescue activity
exerted by NEU4 was further supported by results obtained from Neu4 deficient cells [43,
117]. In Neu4 knockout mice model, a marked vacuolization and lysosomal storage in lung
and spleen cells were observed [118]. In addition, gangliosides profile in the brain showed
an increased level of GD1a and a decrease of GM1, suggesting a possible involvement of
the enzyme in the ganglioside desialylation processes within the central nervous system.
Unlike human Tay-Sachs disease, β-hexosaminidase A-deficient mice remain
asymptomatic to 1 year of age, because the catabolism of GM2 can be partially
compensated by NEU4 pathway. As expected, mice with a double deficiency of NEU4 and
β-hexosaminidase A sufferedd epileptic seizures and rapid neuronal loss accompanied with
GM2 accumulation [118].
The mitochondria localization and predominantly brain distribution of NEU4L
suggest it may have important functions in the brain. In contrast to NEU3, murine NEU4
appears to negatively regulate neurite formation, being down-regulated in Neuro2a cells
during retinoic acid induced differentiation [116]. Furthermore, overexpression of NEU4
resulted in suppression of neurite formation, and its knockdown showed the acceleration
[116]. Interestingly, in this process the endogenous substrate for NEU4 was not
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gangliosides but a 95-kDa glycoprotein, which decreased with cell differentiation. A more
recent study has shown NEU4 regulated neuronal differentiation is at least partially through
degradation of polysialic acids [119]. This mechanism was evidenced in neuroblastoma
Neuro2a cells that were co-transfected with Neu4 and a polysialyltransferases, ST8SiaIV.
In mouse embryonic hippocampal primary neurons, the endogenously expressed NEU4
was found to decrease during the neuronal differentiation. Moreover, NEU4 was partially
co-localized with polysialic acid in neurites and significantly suppressed their outgrowth,
whereas silencing of Neu4 showed the acceleration together with an increase in polysialic
acid expression.
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1.4

Analytical approach
Recent studies are unexpectedly revealing that sialoglycoconjugates contribute in

both general and specific ways to many biological regulatory pathways. This dramatic
development demands more specific, accuracy, and systematic SA detection technologies.
As is described before, both sialyltransferases and sialidases can reflect the total expression
level of SA, and may reveal the underlying molecular mechanisms as well. Other more
desirable approaches should be able to distinguish SA in different locations (such as cell
surface, cytoplasm, and culture medium), different linkages (such as α-2,3 and α-2,6), and
even different underlying structures. First of all, SA on the cell surfaces can be monitored
by several methods, including lectin labeling, boronic acid capturing, metabolic
engineering, and chemical modification [120]. Lectins specifically recognize non-reducing
ends of naturally occurring glycans of glycoconjugates, including glycoproteins and
glycopeptides. However, they can be very large proteins that may suffer from relatively
low affinities, and many lectins can perturb cells by cross-linking receptors, which limits
their application in live cells [121, 122]. Nevertheless, these drawbacks can be
compensated by another carbohydrate recognition molecule, boronic acid, which forms
cyclic esters with diols in different positions of sugars in aqueous solution [123].
Phenylboronic acid selectively binds to SAs and thus has been considered as an innovating
molecular targeting platform for SA detection [124]. Metabolic labeling with SA or SA
precursor analogues allows the introduction of unique functional groups that provide
specific and sensitive detection. However, the poor incorporation efficiency rises great
challenge for the sugar structures as well as the application in broad range of cells [125].
Mass spectrometry is another powerful tool that can quantify SA either with or without
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chemical derivatization, and differentiate SA in various underlying glycan structures [126].
Undoubtedly, mass spectrometry is the potential answer to more complicated questions
arised in SA research.
1.4.1

Lectin-affinity approach to determine SAs on cell surface
SA-specific plant lectins possess historical importance in investigating the

expression and biology of SA [121]. During the past decades, lectins that discriminate
various types of sialylated glycans have been reported (Table II). Since α-2,3 and α-2,6 are
two major forms of SA linkages principally to Gal or GalNAc residues, the lectin searching
has been mostly focus on these two types of sialylated glycoconjugates. Wheat germ
agglutinin (WGA) is initially identified having high specificity towards GlcNAc and its β1,4 linked oligosaccharides. Due to configuration similarities to GlcNAc, SA also shows
direct interaction with WGA regardless the underling linkages [127, 128]. The lectin from
Sambucus nigra (SNA) shows a marked preference for the Neu5Acα2,6Gal/GalNAc over
the α-2,3 structure, thus it has been wildly used to differentiate SA isomers on cell surface
[129]. The Polyporus squamosus lectin (PSL) has specificity for Neu5Acα2,6Gal over the
Neu5Acα2,3 sequence, but unlike SNA, it does not bind to the mucin-derived O-linked
Neu5Acα2,6GalNAc sequence. The strict specificity of the lectin for α-2,6 linked SA
renders this lectin a valuable tool for glycobiological studies and cancer research [130,
131]. Allomyrina dichotoma lectin II (Allo A-II) is another lectin with high specificity for
α-2,6 structure, although it shows a small degree interaction with Galβ1,4GlcNAc [132]. It
provides a useful tool to separate complex type oligosaccharides with the
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Neu5Acα2,6Galβ1,4GlcNAc group from their isomeric oligosaccharides with the
Neu5Acα2,3Galβ1,4GlcNAc group.
Lectins from Maackia amurensis provide powerful tool for α-2,3 linked SA
structure study. Maackia amurensis lectins (MAA) consists of two molecular species, a
strongly hemagglutinating hemagglutinin (MAH) and a strongly mitogenic hemagglutinin
(MAL). MAH binds preferentially to sialylated O-linked glycans containing the
trisaccharide Neu5Acα2,3Galβ1,3GalNAc; MAL preferentially bind to sialylated N-linked
or core 2 O-linked glycans with Neu5Acα2,3Galβ1,4GlcNAc/Glc trisaccharide [133, 134].
Mixtures of MAL and MAH can be used to detect glycans containing α-2,3 linked SA, and
are the most interesting complementary probe to the SNA. These lectins combination can
distinguish among different types of SA linkages and have been used as general tools in
the detection, quantitation, localization, purification and characterization of many
biomolecules containing SA.

There are a few mushroom lectins reacting with

Neu5Acα2,3Gal sequence too. Agrocybe cylindracea lectin (ACG) strongly interacts with
glycoconjugates containing Neu5Acα2,3Galβ1,3GlcNAc/GalNAc sequences [135].
Psathyrella velutina lectin (PVL) and Macrophomina phaseolina agglutinin (MPA)
exhibit high affinity towards sialoglycoproteins possessing trisaccharide α-2,3 linkages and
as potential tools for separation and detection of sialoglycoproteins [136, 137].
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TABLE II: Sialic acid-specific binding lectins
Lectin

Specificity

Sambucus nigra lectin (SNA)

Neu5Ac(α-2,6)Gal/GalNAc

Wheat germ agglutinin (WGA)

Neu5Ac, GlcNAc(β,1-4)GlcNAc

Polyporus squamosus lectin (PSL)

Neu5Ac(α-2,6)Gal

Maackia amurensis hemagglutinin (MAH)

O-linked Neu5Ac(α-2,3)Gal

Allomyrina dichotoma lectin II (Allo A-II)

Neu5Acα2-6Galβ1-4GlcNAc

Maackia amurensis leukoagglutinin (MAL)

N-linked or core 2 O-linked Neu5Ac(α-2,3)Gal

Psathyrella velutina lectin (PVL)

Neu5Acα2,3Galβ1,4GlcNAc, GlcNAc

Agrocybe cylindracea lectin (ACG)

Macrophomina phaseolina agglutinin (MPA)

Neu5Acα2,3Galβ1,3GlcNAc/GalNAc

Neu5Ac(α-2,3)Galβ1,4GlcNAc
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Fluorescent labeled lectins are wildly used in flow cytometry and fluorescent
microscopy for research and diagnosis that related to SA alteration. For example, in one
cancer research, MAL was used to investigate the expression levels of α-2,3 linked SA in
50 primary tumor cases, 50 pair-matched lymph node metastasis tumor samples and in the
MDA-MB-231, T-47D and MCF-7 breast cancer cell lines with different metastatic
potential. The expression of α-2,3 linked SA was analyzed by flow cytometry,
histochemistry and cytochemistry after MAL labeling. As a result, the expression of α-2,3
SA showed a positive correlation with cancer cell metastatic potential, the higher α-2,3
linked SA level the stronger adhesion, invasion and migration activities [138]. Another
study using same approach found high expression of α-2,3 linked SA was associated with
the metastatic potential of human gastric cancer [139]. Moreover, with SNA labeling and
flow cytometric detection, α-2,6 linked SA has been suggested to correlate with the
adhesion of breast cancer cells [140, 141]. However, it should be considered that both α2,3 and α-2,6 sialylation may play different roles in regulating cell adhesion of different
cancer cells when developing potential therapeutics targeting for sialylation.
Furthermore, the strict specificity of lectins to glycan structures provides a valuable
approach to identify the functional glycocnjugates. In a pilot study, a confocal microscopy
method employed four different SA-specific lectins was established to successful
identification and localization of cell surface and intracellular sialoglycoconjugates of
peripheral blood cells [142]. Later, another study analyzed the expression of cell surface
sialoglycoconjugates in Herpetomonas megaseliae by flow cytometry and fluorescence
microscopy using lectins that specifically recognize SA residues [143]. Strong reaction was
detected when parasites treated with slug Limax flavus lectin (LFA), MAA or SNA,
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indicating that molecules containing α-2,3 and α-2,6 sialylgalactosyl sequences were
present in this protozoan. Further study suggested a possible involvement of sialomolecules
in the interaction between this insect trypanosomatid and the invertebrate host. Lectins also
possess potential to selective detection of glycan sialylation on cancer cell surface.
Recently, a study utilized two human mammary epithelial cell lines, HB4A (breast normal
cells) and T47D (breast cancer cells) as a model system to demonstrate differential surface
glycans when treated with SA under nutrient deprivation [144]. Although SA treatment of
both cells resulted in increased activities of α-2,3/6 sialyltransferases, both flow cytometry
and confocal microscopy showed a very strong staining on the membrane of SA-treated
T47D cells, indicating an increase of Neu5Acα2,3Gal on the cell surface.
Although lectins have offered important approach to study cell surface sialylated
structures, there are still several drawbacks. First, some of the plant lectins are glycosylated
and it will complicate the results for study the complex samples that may contain
endogenous lectins which could interact with the glycan of plant lectins [145]. In addition,
many lectins can perturb cells by cross-linking receptors limiting their application in live
cells [146]. At last, unlike other more detailed analysis by mass spectrometry and NMR,
the lectins could only get a category glycan/glyoprotein and must draw assistance from the
high resolution mass spectrometry to identify the structure for further study [147].
Nevertheless, lectins actually give a hand on the research of sialoglycoconjugates on cell
surface and separation siaoglycoconjugates especially from complicated matrix in an
affinity manner.
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1.4.2

Free SA quantification
The SAs in different linkages on cell surfaces can be determined by flow cytometry

and confocal microscopy after specific lectin labeling. However, different approach is
required to analyze SA in other forms and systems. For example, the total amount of SA
expressed by cells, and free SA portion in culture medium and human plasma. To answer
these questions and to systematically study SA in different biological conditions, we
introduced quantitative liquid chromatography coupled mass spectrometry (LC-MS/MS)
to achieve accuracy and robust detection of SA in matrices, such as human plasma, cell
culture medium, and cell lysate.
The special 9-carbon monosaccharide with one carboxylic acid structure provides
no UV absorption, which initially vanished the possibility to directly quantify SA.
Derivatization reagents with UV absorption such as resorcinol [148] and thiobarbituric acid
[149] enables the detection of SA with colorimetric assay. In order to improve the detection
sensitivity and specificity, new fluorometric methods were developed with modified
thiobarbituric acid derivatization [150], or mild periodate oxidation coupled with Hantzsch
reaction [151]. However, neither colorimetric nor fluorometir assays could differentiate SA
from other interference, thus limiting their application in complex biological samples.
Reversed-phase HPLC has the advantage of quantitatively differentiating various forms of
SAs and limits the interference from matrix. For example, HPLC-UV with per-Obenzoylation has been reported to determine Neu5Gc and Neu5Ac in the culture media and
cell-associated glycoconjugates from cancer cells [152]. However, the revolutionary
advance of SAs quantification started after the development of quinoxaline derivatization
followed by HPLC with fluorescence detection (Figure 5). Derivatization reagents such as
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1,2-diamino-4,5-dimethoxybenzene (DDB) [153], o-phenylenediamine (OPD) [154], and
1,2-Diamino-4,5-methylenedioxybenzene (DMB) [155, 156] are initially reported to give
strong fluorescent intensity. Among them DMB is the most sensitive one with high
derivatization efficiency, thus it has been commonly used for SAs derivatization and also
in commercial SAs quantification kits. However, both DMB reagent and its SAs derivative
are very instable due to their light and oxygen sensitivity. Fresh DMB solution has to be
prepared every day, which is time consuming and increases the cost for the expensive DMB
reagent. In our lab we have reported two stable and cost-effective quinoxaline
derivatization reagents, 3,4-diaminotoluene (DAT) [157] and 4,5-dimethylbenzene-1,2diamine (DMBA) [158], both of which give high reaction efficiency and intense signal in
fluorescence and mass spectrometry quantification.

36

Figure 5:

Quinoxaline derivitization of SAs
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The LC-MS/MS quantification coupled with quinoxalinone derivatization
possesses high sensitivity and high resolution, which has provided a powerful tool for SAs
analysis in the complex biology samples [159-161]. A very successful application is to
study SA diversity, and identify small amount of unexpected SAs or new members of their
family [160, 161]. One study used electrospray ionization-mass spectrometry (ESI-MS) to
characterize SAs after the HPLC separation of their DMB derivatives from different
biology source [160]. As a result, 28 different SAs including more than 10 new species
were identified. Furthermore, this approach was able to characterize the sulfate esters of
SAs such as Neu5Ac8S and Neu5Gc8S, which were not detected using other
methodologies. Aother similar study used LC-MS/MS to compare SA species and
distributions in different tissues of rats and mice [161]. Results showed a wide variety of
SAs existed in tissue-specific manner in mice and rats, and highly acetylated SAs and 8O-sulfo-Neu5Ac were commonly distributed in all the organs examined. For example,
mouse sera contained Neu5Gc as the major SA, but Neu5Ac and Neu5,9Ac2 were the
major components in rat sera. Sublingual and submaxillary glands of rats showed wide
distributions of various SAs, but those of mice contained simple SA composed of Neu5Ac
as the major one. Although the reason different SAs are found in these tissues is not clear,
different enzymes such as acetyl transferase and sulfotransferase play some significant
roles.
The derivatization method indeed provides valuable tool to identify and quantify
(if the standard compounds are available) SA species in various biology samples. However,
the sample preparation is tedious and time consuming, which limits its application in large
scale sample analysis, such as in clinical case. One of the most attractive area in clinical
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application is the diagnosis of SA storage disease [162-164]. SA storage diseases (SSDs)
are inborn error resulting from defects in the lysosomal membrane protein sialin, which
leads to accumulation of SA in tissues, fibroblasts, and urine. Defective free SA transport
can be established by quantification of free SA in urine. Direct SA quantification with LCMS/MS has been reported to be more rapid, accurate, and sensitive than earlier methods
for SA detection in the urine [162]. In one clinical study, free SA in the urine samples was
separated by amino propyl guard column with gradient elution, and then detected by triplequadrupole mass spectrometer in negative mode [162]. This method was used to quantify
free SA in urine samples from 72 control people and 3 SSDs patients. The results showed
this method can successfully distinguish the SSDs from the healthy individuals. For
example, patients at 1.2 years old had SA of 111.5 mmol/mol creatinine, compared to the
normal range 0.7-56.9 mmol/mol creatinine obtained from 20 normal people. In another
clinical study, both urine free and total SA were analyzed by a newly developed LCMS/MS approach using an Atlantis dC18 analytical column to separate SA from the
interferences [163]. Free SA was analyzed directly after a simple filtration step, and total
SA was obtained by one step acid hydrolysis. This method achieved a semi-automated
sample preparation in combination with a runtime of 6 min, which made it suitable for high
throughput analysis. Moreover, based on urine samples from 589 individuals and 11 SA
metabolism deficient patients, age-related reference values for free SA, total SA and
conjugated SA were determined and improved the diagnostic efficacy. Later a similar LCMS/MS approach with small modification was used to determine free and conjugated SA
in amniotic fluid supernatant (AFS), which is also used for SSDs screening test [164]. The
whole procedures from sample preparation to MS analysis can be performed in 2-4 h.
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Reference values in AFS were 0-8.2 μmol/L for 15-25 weeks of gestation and 3.2-12.0
μmol/L for 26-38 weeks of gestation. In AFS samples from five fetuses affected with
infantile SSD free SA was 23.9-58.9 μmol/L demonstrating that this method was able to
discriminate infantile SSD pregnancies from normal ones.

40

1.5

Reference

1.

Varki A, Schauer R. Sialic Acids. In: Varki A, Cummings RD, Esko JD, Freeze
HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. 2009. Essentials of
Glycobiology. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory
Press. Chapter 14.

2.

Rambourg A, Leblond CP. 1967. Electron microscope observations on the
carbohydrate-rich cell coat present at the surface of cells in the rat. J Cell Biol. 32:
27-53.

3.

Angata T, Varki A. 2002. Chemical diversity in the sialic acids and related α-keto
acids: an evolutionary perspective. Chem. Rev. 102: 439-469.

4.

Cohen M, Varki A. 2010. The sialome-far more than the sum of its parts. OMICS.
14:455-464.

5.

Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien
S, Delannoy P. 2001. The human sialyltransferase family. Biochimie. 83: 727-737.

6.

Varki A. 2001. Loss of N-glycolylneuraminic acid in humans: Mechanisms,
consequences, and implications for hominid evolution. Am J Phys Anthropol. Suppl
33: 54-69.

7.

Varki NM, Varki A. 2007. Diversity in cell surface sialic acid presentations:
implications for biology and disease. Lab Invest. 87: 851-857.

8.

Varki A. 2007. Glycan-based interactions involving vertebrate sialic-acidrecognizing proteins. Nature. 446: 1023-1029.

9.

Schauer R. 2009. Sialic acids as regulators of molecular and cellular interactions.
Curr Opin Struct Biol. 19: 507-514.

41

10.

Varki A. 2008. Sialic acids in human health and disease. Trends Mol. Med.14: 351360.

11.

Kumlin U, Olofsson S, Dimock K, Arnberg N. 2008. Sialic acid tissue distribution
and influenza virus tropism. Influenza Other Respir Viruses. 2: 147-154.

12.

Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. 2008. Evolving
complexities of influenza virus and its receptors. Trends Microbiol. 16: 149-157.

13.

Yuyama Y, Yoshimatsu K, Ono E, Saito M, Naiki M. 1993. Postnatal change of
pig intestinal ganglioside bound by Escherichia coli with K99 fimbriae. J Biochem.
113: 488-492.

14.

Sharon N, Lis H. 2004. History of lectins: from hemagglutinins to biological
recognition molecules. Glycobiology. 14(11):53R-62R.

15.

Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrín D, Stehle T. 2015.
Structural basis for sialic acid-mediated self-recognition by complement factor H.
Nat Chem Biol. 11:77-82.

16.

Kopp A, Hebecker M, Svobodová E, Józsi M. 2012. Factor h: a complement
regulator in health and disease, and a mediator of cellular interactions.
Biomolecules. 2:46-75.

17.

Ley K. 2003. The role of selectins in inflammation and disease. Trends Mol Med.
9: 263-268.

18.

Zarbock A, Ley K, McEver RP, Hidalgo A. 2011. Leukocyte ligands for endothelial
selectins: specialized glycoconjugates that mediate rolling and signaling under
flow. Blood. 118: 6743-6751.
42

19.

Varki A, Angata T. 2006. Siglecs-the major subfamily of I-type lectins.
Glycobiology. 16: 1R-27R.

20.

Pillai S, Netravali IA, Cariappa A, Mattoo H. 2012. Siglecs and immune regulation.
Annu Rev Immunol. 30: 357-392.

21.

Macauley MS, Crocker PR, Paulson JC. 2014. Siglec-mediated regulation of
immune cell function in disease. Nat Rev Immunol. 14: 653-666.

22.

Chang YC, Nizet V. 2014. The interplay between Siglecs and sialylated pathogens.
Glycobiology. 24: 818-825.

23.

Varki A, Gagneux P. 2012. Multifarious roles of sialic acids in immunity. Ann N Y
Acad Sci. 1253:16-36.

24.

von Itzstein M. 2007. The war against influenza: discovery and development of
sialidase inhibitors. Nat Rev Drug Discov. 6: 967-974.

25.

Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VD, Yarema KJ. 2008.
Metabolic glycoengineering: sialic acid and beyond. Glycobiology. 19:1382-1401.

26.

Warren L, Felsenfeld H. 1962. The biosynthesis of sialic acids. J Biol Chem. 237:
1421-1431.

27.

Li Y, Chen X. 2012. Sialic acid metabolism and sialyltransferases: natural functions
and applications. Appl Microbiol Biotechnol. 94: 887-905.

28.

Hinderlich S, Weidemann W, Yardeni T, Horstkorte R, Huizing M. 2015. UDPGlcNAc 2-Epimerase/ManNAc Kinase (GNE): A Master Regulator of Sialic Acid
Synthesis. Top Curr Chem. 366: 97-137.

29.

Davies LR, Varki A. 2015. Why Is N-Glycolylneuraminic Acid Rare in the
Vertebrate Brain? Top Curr Chem. 366: 31-54.
43

30.

Mandal C, Schwartz-Albiez R, Vlasak R. 2015. Functions and Biosynthesis of OAcetylated Sialic Acids. Top Curr Chem. 366: 1-30.

31.

Monica TJ, Andersen DC, Goochee CF. 1997. A mathematical model of sialylation
of N-linked oligosaccharides in the trans-Golgi network. Glycobiology. 7: 515-21.

32.

Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C. 2011.
Current trends in the structure-activity relationships of sialyltransferases.
Glycobiology. 21: 716-726.

33.

Tsuji S. 1996. Molecular cloning and functional analysis of sialyltransferases. J
Biochem. 120: 1-13.

34.

Harduin-Lepers A, Mollicone R, Delannoy P, Oriol R. 2005. The animal
sialyltransferases and sialyltransferase-related genes: a phylogenetic approach.
Glycobiology. 15: 805-817.

35.

Wang L, Liu Y, Wu L, Sun XL. 2016. Sialyltransferase inhibition and recent
advances. Biochim Biophys Acta. 1864:143-153.

36.

Schauer R. 2004. Sialic acids: fascinating sugars in higher animals and man.
Zoology (Jena). 107: 49-64.

37.

Achyuthan KE, Achyuthan AM. 2001. Comparative enzymology, biochemistry and
pathophysiology of human exo-alpha-sialidases (neuraminidases). Comp Biochem
Physiol B Biochem Mol Biol. 129: 29-64.

38.

Monti E, Bonten E, D'Azzo A, Bresciani R, Venerando B, Borsani G, Schauer R,
Tettamanti G. 2010. Sialidases in vertebrates: a family of enzymes tailored for
several cell functions. Adv Carbohydr Chem Biochem. 64: 403-479.
44

39.

Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. 1996.
Characterization of human lysosomal neuraminidase defines the molecular basis of
the metabolic storage disorder sialidosis. Genes Dev. 10: 3156-3169.

40.

Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai
G, Sodeoka M, von Itzstein M, Miyagi T. 2008. Limited inhibitory effects of
oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother. 52:
3484-3491.

41.

Koseki K, Wada T, Hosono M, Hata K, Yamaguchi K, Nitta K, Miyagi T. 2012.
Human cytosolic sialidase NEU2-low general tissue expression but involvement in
PC-3 prostate cancer cell survival. Biochem Biophys Res Commun. 428: 142-149.

42.

Monti E, Bassi MT, Papini N, Riboni M, Manzoni M, Venerando B, Croci G, Preti
A, Ballabio A, Tettamanti G, Borsani G. 2000. Identification and expression of
NEU3, a novel human sialidase associated to the plasma membrane. Biochem J.
349:343-351.

43.

Seyrantepe V, Landry K, Trudel S, Hassan JA, Morales CR, Pshezhetsky AV. 2004.
Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to
sialidosis and galactosialidosis cells. J Biol Chem. 279: 37021-37029.

44.

Miyagi T, Yamaguchi K. 2012. Mammalian sialidases: physiological and
pathological roles in cellular functions. Glycobiology. 22: 880-896.

45.

van der Spoel A, Bonten E, d'Azzo A. 1998. Transport of human lysosomal
neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO
J. 17: 1588-1597.
45

46.

Bonten EJ, Campos Y, Zaitsev V, Nourse A, Waddell B, Lewis W, Taylor G,
d'Azzo A. 2009. Heterodimerization of the sialidase NEU1 with the chaperone
protective protein/cathepsin A prevents its premature oligomerization. J Biol Chem.
284: 28430-28441.

47.

Caciotti A, Catarzi S, Tonin R, Lugli L, Perez CR, Michelakakis H, Mavridou I,
Donati MA, Guerrini R, d'Azzo A, Morrone A. 2013. Galactosialidosis: review
and analysis of CTSA gene mutations. Orphanet J Rare Dis. 8:114-122.

48.

d'Azzo A, Machado E, Annunziata I. 2015. Pathogenesis, Emerging therapeutic
targets and Treatment in Sialidosis. Expert Opin Orphan Drugs. 3: 491-504.

49.

Yogalingam G, Bonten EJ, van de Vlekkert D, Hu H, Moshiach S, Connell SA,
d'Azzo A. 2008. Neuraminidase 1 is a negative regulator of lysosomal exocytosis.
Dev Cell. 15: 74-86.

50.

Kima PE, Burleigh B, Andrews NW. 2000. Surface-targeted lysosomal membrane
glycoprotein-1 (Lamp-1) enhances lysosome exocytosis and cell invasion by
Trypanosoma cruzi. Cell Microbiol. 2: 477-486.

51.

Wu X, Steigelman KA, Bonten E, Hu H, He W, Ren T, Zuo J, d'Azzo A. 2010.
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal
cells contribute to hearing loss in neuraminidase 1-deficient mice. Biochim Biophys
Acta. 1802: 259-268.

52.

Machado E, White-Gilbertson S, van de Vlekkert D, Janke L, Moshiach S, Campos
Y, Finkelstein D, Gomero E, Mosca R, Qiu X, Morton CL, Annunziata I, d'Azzo
A. 2015. Regulated lysosomal exocytosis mediates cancer progression. Sci Adv. 1:
e1500603.

46

53.

Kearse KP, Cassatt DR, Kaplan AM, Cohen DA. 1988. The requirement for surface
Ig signaling as a prerequisite for T cell:B cell interactions. A possible role for
desialylation. J Immunol. 140: 1770-1778.

54.

Bagriaçik EU, Miller KS. 1999. Cell surface sialic acid and the regulation of
immune cell interactions: the neuraminidase effect reconsidered. Glycobiology. 9:
267-275.

55.

Chen XP, Enioutina EY, Daynes RA. 1997. The control of IL-4 gene expression in
activated murine T lymphocytes: a novel role for neu-1 sialidase. J Immunol. 158:
3070-3080.

56.

Nan X, Carubelli I, Stamatos NM. 2007. Sialidase expression in activated human
T lymphocytes influences production of IFN-gamma. J Leukoc Biol. 81: 284-296.

57.

Landolfi NF, Cook RG. 1986. Activated T-lymphocytes express class I molecules
which are hyposialylated compared to other lymphocyte populations. Mol
Immunol. 23: 297-309.

58.

Yamamoto N, Kumashiro R. 1993. Conversion of vitamin D3 binding protein
(group-specific component) to a macrophage activating factor by the stepwise
action of beta-galactosidase of B cells and sialidase of T cells. J Immunol. 151:
2794-2802.

59.

Wang D, Ozhegov E, Wang L, Zhou A, Nie H, Li Y, Sun XL. 2016. Sialylation
and desialylation dynamics of monocytes upon differentiation and polarization to
macrophages. Glycoconj J. doi:10.1007/s10719-016-9664-4.

60.

Liang F, Seyrantepe V, Landry K, Ahmad R, Ahmad A, Stamatos NM, Pshezhetsky
AV. 2006. Monocyte differentiation up-regulates the expression of the lysosomal
47

sialidase, Neu1, and triggers its targeting to the plasma membrane via major
histocompatibility complex class II-positive compartments. J Biol Chem. 281:
27526-27538.
61.

Stamatos NM, Liang F, Nan X, Landry K, Cross AS, Wang LX, Pshezhetsky AV.
2005. Differential expression of endogenous sialidases of human monocytes during
cellular differentiation into macrophages. FEBS J. 272: 2545-2556.

62.

Seyrantepe V, Iannello A, Liang F, Kanshin E, Jayanth P, Samarani S, Szewczuk
MR, Ahmad A, Pshezhetsky AV. 2010. Regulation of phagocytosis in macrophages
by neuraminidase 1. J Biol Chem. 285: 206-215.

63.

Amith SR, Jayanth P, Franchuk S, Siddiqui S, Seyrantepe V, Gee K, Basta S,
Beyaert R, Pshezhetsky AV, Szewczuk MR. 2009. Dependence of pathogen
molecule-induced toll-like receptor activation and cell function on Neu1 sialidase.
Glycoconj J. 26: 1197-1212.

64.

Amith SR, Jayanth P, Franchuk S, Finlay T, Seyrantepe V, Beyaert R, Pshezhetsky
AV, Szewczuk MR. 2010. Neu1 desialylation of sialyl alpha-2,3-linked betagalactosyl residues of TOLL-like receptor 4 is essential for receptor activation and
cellular signaling. Cell Signal. 22: 314-324.

65.

Chen GY, Brown NK, Wu W, Khedri Z, Yu H, Chen X, van de Vlekkert D, D'Azzo
A, Zheng P, Liu Y. 2014. Broad and direct interaction between TLR and Siglec
families of pattern recognition receptors and its regulation by Neu1. Elife. 3:
e04066.

48

66.

Hinek A, Pshezhetsky AV, von Itzstein M, Starcher B. 2006. Lysosomal sialidase
(neuraminidase-1) is targeted to the cell surface in a multiprotein complex that
facilitates elastic fiber assembly. J Biol Chem. 281: 3698-3710.

67.

Starcher B, d'Azzo A, Keller PW, Rao GK, Nadarajah D, Hinek A. 2008.
Neuraminidase-1 is required for the normal assembly of elastic fibers. Am J Physiol
Lung Cell Mol Physiol. 295: L637-647.

68.

Duca L, Blanchevoye C, Cantarelli B, Ghoneim C, Dedieu S, Delacoux F,
Hornebeck W, Hinek A, Martiny L, Debelle L. 2007. The elastin receptor complex
transduces signals through the catalytic activity of its Neu-1 subunit. J Biol Chem.
282: 12484-12491.

69.

Guertl B, Noehammer C, Hoefler G. 2000. Metabolic cardiomyopathies. Int J Exp
Pathol. 81: 349-372.

70.

Ghosh S. 2015. Sialic acids: biomarkers in endocrinal cancers. Glycoconj J. 32: 7985.

71.

Miyagi T, Wada T, Yamaguchi K, Shiozaki K, Sato I, Kakugawa Y, Yamanami H,
Fujiya T. 2008. Human sialidase as a cancer marker. Proteomics. 8: 3303-3311.

72.

Pshezhetsky AV, Hinek A. 2011. Where catabolism meets signalling:
neuraminidase 1 as a modulator of cell receptors. Glycoconj J. 28: 441-452.

73.

Miyagi T, Sato K, Hata K, Taniguchi S. 1994. Metastatic potential of transformed
rat 3Y1 cell lines is inversely correlated with lysosomal-type sialidase activity.
FEBS Lett. 349: 255-259.

74.

Sawada M, Moriya S, Saito S, Shineha R, Satomi S, Yamori T, Tsuruo T, Kannagi
R, Miyagi T. 2002. Reduced sialidase expression in highly metastatic variants of
49

mouse colon adenocarcinoma 26 and retardation of their metastatic ability by
sialidase overexpression. Int J Cancer. 97: 180-185.
75.

Kato T, Wang Y, Yamaguchi K, Milner CM, Shineha R, Satomi S, Miyagi T. 2001.
Overexpression of lysosomal-type sialidase leads to suppression of metastasis
associated with reversion of malignant phenotype in murine B16 melanoma cells.
Int J Cancer. 92: 797-804.

76.

Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, Sakuraba H,
Miyagi T. 2009. Contribution of sialidase NEU1 to suppression of metastasis of
human colon cancer cells through desialylation of integrin beta4. Oncogene. 28:
1218-1229.

77.

Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. 2011. miR-125b
promotes growth of prostate cancer xenograft tumor through targeting proapoptotic genes. Prostate. 71: 538-549.

78.

Ren LR, Zhang LP, Huang SY, Zhu YF, Li WJ, Fang SY, Shen L, Gao YL. 2016.
Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in
human ovarian cancer. Mol Cell Biochem. 411: 213-219.

79.

Haxho F, Neufeld RJ, Szewczuk MR. 2016. Neuraminidase-1: A novel therapeutic
target in multistage tumorigenesis. Oncotarget. doi: 10.18632/oncotarget.8396.

80.

Gilmour AM, Abdulkhalek S, Cheng TS, Alghamdi F, Jayanth P, O'Shea LK, Geen
O, Arvizu LA, Szewczuk MR. 2013. A novel epidermal growth factor receptorsignaling platform and its targeted translation in pancreatic cancer. Cell Signal. 25:
2587-2603.
50

81.

O'Shea LK, Abdulkhalek S, Allison S, Neufeld RJ, Szewczuk MR. 2014.
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®)
disables cancer cell survival in human pancreatic cancer with acquired
chemoresistance. Onco Targets Ther. 7: 117-134.

82.

Miyagi T, Konno K, Emori Y, Kawasaki H, Suzuki K, Yasui A, Tsuik S. 1993.
Molecular cloning and expression of cDNA encoding rat skeletal muscle cytosolic
sialidase. J Biol Chem. 268: 26435-26440.

83.

Tringali C, Papini N, Fusi P, Croci G, Borsani G, Preti A, Tortora P, Tettamanti G,
Venerando B, Monti E. 2004. Properties of recombinant human cytosolic sialidase
HsNEU2. The enzyme hydrolyzes monomerically dispersed GM1 ganglioside
molecules. J Biol Chem. 279: 3169-3179.

84.

Sato K, Miyagi T. 1996. Involvement of an endogenous sialidase in skeletal muscle
cell differentiation. Biochem Biophys Res Commun. 221: 826-830.

85.

Fanzani A, Giuliani R, Colombo F, Zizioli D, Presta M, Preti A, Marchesini S.
2003. Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation
in C2C12 cells. FEBS Lett. 547: 183-188.

86.

Suzuki N, Aoki M, Hinuma Y, Takahashi T, Onodera Y, Ishigaki A, Kato M,
Warita H, Tateyama M, Itoyama Y. 2005. Expression profiling with progression of
dystrophic change in dysferlin-deficient mice (SJL). Neurosci Res. 52: 47-60.

87.

Fanzani A, Colombo F, Giuliani R, Preti A, Marchesini S. 2006. Insulin-like growth
factor 1 signaling regulates cytosolic sialidase Neu2 expression during myoblast
differentiation and hypertrophy. FEBS J. 273: 3709-3721.
51

88.

Fanzani A, Giuliani R, Colombo F, Rossi S, Stoppani E, Martinet W, Preti A,
Marchesini S. 2008. The enzymatic activity of sialidase Neu2 is inversely regulated
during in vitro myoblast hypertrophy and atrophy. Biochem Biophys Res Commun.
370: 376-381.

89.

Oehler C, Kopitz J, Cantz M. 2002. Substrate specificity and inhibitor studies of a
membrane-bound ganglioside sialidase isolated from human brain tissue. Biol
Chem. 383: 1735-1742.

90.

Ha KT, Lee YC, Cho SH, Kim JK, Kim CH. 2004. Molecular characterization of
membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli. Mol
Cells. 17: 267-273.

91.

Li SC, Li YT, Moriya S, Miyagi T. 2001. Degradation of G(M1) and G(M2) by
mammalian sialidases. Biochem J. 360: 233-237.

92.

Papini N, Anastasia L, Tringali C, Croci G, Bresciani R, Yamaguchi K, Miyagi T,
Preti A, Prinetti A, Prioni S, Sonnino S, Tettamanti G, Venerando B, Monti E. 2004.
The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside
pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J
Biol Chem. 279: 16989-16995.

93.

Zanchetti G, Colombi P, Manzoni M, Anastasia L, Caimi L, Borsani G, Venerando
B, Tettamanti G, Preti A, Monti E, Bresciani R. 2007. Sialidase NEU3 is a
peripheral membrane protein localized on the cell surface and in endosomal
structures. Biochem J. 408: 211-219.

52

94.

Kalka D, von Reitzenstein C, Kopitz J, Cantz M. 2001. The plasma membrane
ganglioside sialidase cofractionates with markers of lipid rafts. Biochem Biophys
Res Commun. 283:989-993.

95.

Wang Y, Yamaguchi K, Wada T, Hata K, Zhao X, Fujimoto T, Miyagi T. 2002. A
close association of the ganglioside-specific sialidase Neu3 with caveolin in
membrane microdomains. J Biol Chem. 277: 26252-26259.

96.

Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C.
2008. The Csk-binding protein PAG regulates PDGF-induced Src mitogenic
signaling via GM1. J Cell Biol. 182: 603-614.

97.

Kopitz J, von Reitzenstein C, Mühl C, Cantz M. 1994. Role of plasma membrane
ganglioside sialidase of human neuroblastoma cells in growth control and
differentiation. Biochem Biophys Res Commun. 199:1188-1193.

98.

Hasegawa T, Yamaguchi K, Wada T, Takeda A, Itoyama Y, Miyagi T. 2000.
Molecular cloning of mouse ganglioside sialidase and its increased expression in
Neuro2a cell differentiation. J Biol Chem. 275: 8007-8015.

99.

Rodriguez JA, Piddini E, Hasegawa T, Miyagi T, Dotti CG. 2001. Plasma
membrane ganglioside sialidase regulates axonal growth and regeneration in
hippocampal neurons in culture. J Neurosci. 21:8387-8395.

100.

Kappagantula S, Andrews MR, Cheah M, Abad-Rodriguez J, Dotti CG, Fawcett
JW. 2014. Neu3 sialidase-mediated ganglioside conversion is necessary for axon
regeneration and is blocked in CNS axons. J Neurosci. 34: 2477-2492.

101.

Vyas AA, Patel HV, Fromholt SE, Heffer-Lauc M, Vyas KA, Dang J, Schachner
M, Schnaar RL. 2002. Gangliosides are functional nerve cell ligands for myelin53

associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad
Sci U S A. 99:8412-8417.
102.

Mountney A, Zahner MR, Lorenzini I, Oudega M, Schramm LP, Schnaar RL. 2010.
Sialidase enhances recovery from spinal cord contusion injury. Proc Natl Acad Sci
U S A. 107: 11561-11566.

103.

Da Silva JS, Hasegawa T, Miyagi T, Dotti CG, Abad-Rodriguez J. 2005.
Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat
Neurosci. 8: 606-615.

104.

Anastasia L, Papini N, Colazzo F, Palazzolo G, Tringali C, Dileo L, Piccoli M,
Conforti E, Sitzia C, Monti E, Sampaolesi M, Tettamanti G, Venerando B. 2008.
NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus
favoring their differentiation and protecting them from apoptosis. J Biol Chem. 283:
36265-36271.

105.

Papini N, Anastasia L, Tringali C, Dileo L, Carubelli I, Sampaolesi M, Monti E,
Tettamanti G, Venerando B. 2012. MmNEU3 sialidase over-expression in C2C12
myoblasts delays differentiation and induces hypertrophic myotube formation. J
Cell Biochem. 113:2967-2978.

106.

Scaringi R, Piccoli M, Papini N, Cirillo F, Conforti E, Bergante S, Tringali C,
Garatti A, Gelfi C, Venerando B, Menicanti L, Tettamanti G, Anastasia L. 2013.
NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from
apoptosis through the activation of the epidermal growth factor receptor signaling
pathway and the hypoxia-inducible factor (HIF)-1α. J Biol Chem. 288: 3153-3162.
54

107.

Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, Miyagi T.
2002. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3)
in human colon cancer and its involvement in apoptosis suppression. Proc Natl
Acad Sci U S A. 99: 10718-10723.

108.

Wada T, Hata K, Yamaguchi K, Shiozaki K, Koseki K, Moriya S, Miyagi T. 2007.
A crucial role of plasma membrane-associated sialidase in the survival of human
cancer cells. Oncogene. 26: 2483-2490.

109.

Miyagi T, Wada T, Yamaguchi K, Hata K, Shiozaki K. 2008. Plasma membraneassociated sialidase as a crucial regulator of transmembrane signalling. J
Biochem.144: 279-285.

110.

Yamaguchi K, Hata K, Koseki K, Shiozaki K, Akita H, Wada T, Moriya S, Miyagi
T. 2005. Evidence for mitochondrial localization of a novel human sialidase
(NEU4). Biochem J. 390: 85-93.

111.

Bigi A, Morosi L, Pozzi C, Forcella M, Tettamanti G, Venerando B, Monti E, Fusi
P. 2010. Human sialidase NEU4 long and short are extrinsic proteins bound to outer
mitochondrial

membrane

and

the

endoplasmic

reticulum,

respectively.

Glycobiology. 20: 148-157.
112.

Smutova V, Albohy A, Pan X, Korchagina E, Miyagi T, Bovin N, Cairo CW,
Pshezhetsky AV. 2014. Structural basis for substrate specificity of mammalian
neuraminidases. PLoS One. 9: e106320.

113.

Malisan F, Testi R. 2002. GD3 ganglioside and apoptosis. Biochim Biophys Acta.
1585: 179-187.
55

114.

Hasegawa T, Sugeno N, Takeda A, Matsuzaki-Kobayashi M, Kikuchi A, Furukawa
K, Miyagi T, Itoyama Y. 2007. Role of Neu4L sialidase and its substrate
ganglioside GD3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett.
581: 406-412.

115.

Comelli EM, Amado M, Lustig SR, Paulson JC. 2003. Identification and expression
of Neu4, a novel murine sialidase. Gene. 321: 155-61.

116.

Shiozaki K, Koseki K, Yamaguchi K, Shiozaki M, Narimatsu H, Miyagi T. 2009.
Developmental change of sialidase neu4 expression in murine brain and its
involvement in the regulation of neuronal cell differentiation. J Biol Chem. 284:
21157-21164.

117.

Seyrantepe V, Canuel M, Carpentier S, Landry K, Durand S, Liang F, Zeng J,
Caqueret A, Gravel RA, Marchesini S, Zwingmann C, Michaud J, Morales CR,
Levade T, Pshezhetsky AV. 2008. Mice deficient in Neu4 sialidase exhibit
abnormal ganglioside catabolism and lysosomal storage. Hum Mol Genet. 17:
1556-1568.

118.

Seyrantepe V, Lema P, Caqueret A, Dridi L, Bel Hadj S, Carpentier S, Boucher F,
Levade T, Carmant L, Gravel RA, Hamel E, Vachon P, Di Cristo G, Michaud JL,
Morales CR, Pshezhetsky AV. 2010. Mice doubly-deficient in lysosomal
hexosaminidase A and neuraminidase 4 show epileptic crises and rapid neuronal
loss. PLoS Genet. 6: e1001118.

119.

Takahashi K, Mitoma J, Hosono M, Shiozaki K, Sato C, Yamaguchi K, Kitajima
K, Higashi H, Nitta K, Shima H, Miyagi T. 2012. Sialidase NEU4 hydrolyzes
56

polysialic acids of neural cell adhesion molecules and negatively regulates neurite
formation by hippocampal neurons. J Biol Chem. 287: 14816-14826.
120.

Chen X, Varki A. 2010. Advances in the biology and chemistry of sialic acids. ACS
Chem Biol. 5: 163-176.

121.

Lehmann F, Tiralongo E, Tiralongo J. 2006. Sialic acid-specific lectins:
occurrence, specificity and function. Cell Mol Life Sci. 63: 1331-1354.

122.

Wu AM, Lisowska E, Duk M, Yang Z. 2009. Lectins as tools in glycoconjugate
research. Glycoconj J. 26: 899-913.

123.

Sun X, Zhai W, Fossey JS, James TD. 2016. Boronic acids for fluorescence
imaging of carbohydrates. Chem Commun (Camb). 52: 3456-3469.

124.

Otsuka H, Uchimura E, Koshino H, Okano T, Kataoka K. 2003. Anomalous
binding profile of phenylboronic acid with N-acetylneuraminic acid (Neu5Ac) in
aqueous solution with varying pH. J Am Chem Soc. 125: 3493-3502.

125.

Campbell CT, Sampathkumar SG, Yarema KJ. 2007. Metabolic oligosaccharide
engineering: perspectives, applications, and future directions. Mol Biosyst. 3:187194.

126.

Nie H, Li Y, Sun XL. 2012. Recent advances in sialic acid-focused glycomics. J
Proteomics. 75: 3098-3112.

127.

Bhavanandan VP, Katlic AW. 1979. The interaction of wheat germ agglutinin with
sialoglycoproteins. The role of sialic acid. J Biol Chem. 254: 4000-4008.

128.

Monsigny M, Roche AC, Sene C, Maget-Dana R, Delmotte F. 1980. Sugar-lectin
interactions: how does wheat-germ agglutinin bind sialoglycoconjugates? Eur J
Biochem. 104: 147-153.

57

129.

Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B, Peumans
WJ. 1987. The elderberry (Sambucus nigra L.) bark lectin recognizes the
Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem. 262: 1596-1601.

130.

Mo H, Winter HC, Goldstein IJ. 2000. Purification and characterization of a
Neu5Acalpha2-6Galbeta1-4Glc/GlcNAc-specific lectin from the fruiting body of
the polypore mushroom Polyporus squamosus. J Biol Chem. 275: 10623-10629.

131.

Kadirvelraj R, Grant OC, Goldstein IJ, Winter HC, Tateno H, Fadda E, Woods RJ.
2011. Structure and binding analysis of Polyporus squamosus lectin in complex
with the Neu5Ac{alpha}2-6Gal{beta}1-4GlcNAc human-type influenza receptor.
Glycobiology. 21: 973-984.

132.

Yamashita K, Umetsu K, Suzuki T, Iwaki Y, Endo T, Kobata A. 1988.
Carbohydrate binding specificity of immobilized Allomyrina dichotoma lectin II. J
Biol Chem. 263: 17482-17489.

133.

Knibbs RN, Goldstein IJ, Ratcliffe RM, Shibuya N. 1991. Characterization of the
carbohydrate binding specificity of the leukoagglutinating lectin from Maackia
amurensis. Comparison with other sialic acid-specific lectins. J Biol Chem. 266:8388.

134.

Konami Y, Yamamoto K, Osawa T, Irimura T. 1994. Strong affinity of Maackia
amurensis hemagglutinin (MAH) for sialic acid-containing Ser/Thr-linked
carbohydrate chains of N-terminal octapeptides from human glycophorin A. FEBS
Lett. 342: 334-338.

58

135.

Yagi F, Miyamoto M, Abe T, Minami Y, Tadera K, Goldstein IJ. 1997. Purification
and carbohydrate-binding specificity of Agrocybe cylindracea lectin. Glycoconj J.
14: 281-288.

136.

Ueda H, Matsumoto H, Takahashi N, Ogawa H. 2002. Psathyrella velutina
Mushroom Lectin Exhibits High Affinity toward Sialoglycoproteins Possessing
Terminal N-Acetylneuraminic Acid alpha 2,3-Linked to Penultimate Galactose
Residues of Trisialyl N-Glycans. Comparison with other sialic acid-specific lectins.
J Biol Chem. 277: 24916-24925.

137.

Bhowal J, Guha AK, Chatterjee BP. 2005. Purification and molecular
characterization of a sialic acid specific lectin from the phytopathogenic fungus
Macrophomina phaseolina. Carbohydr Res. 340: 1973-1982.

138.

Cui H, Lin Y, Yue L, Zhao X, Liu J. 2012. Differential expression of the α2,3-sialic
acid residues in breast cancer is associated with metastatic potential. Oncol Rep.
25: 1365-1371.

139.

Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, Zhou L, Mu YL, Tang W, Wang YS.
2009. High expression of alpha 2, 3-linked sialic acid residues is associated with
the metastatic potential of human gastric cancer. Cancer Detect Prev. 32: 437-443.

140.

Lin S, Kemmner W, Grigull S, Schlag PM. 2002. Cell surface alpha 2,6 sialylation
affects adhesion of breast carcinoma cells. Exp Cell Res. 276:101-110.

141.

Yuan Y, Wu L, Shen S, Wu S, Burdick MM. 2016. Effect of alpha 2,6 sialylation
on integrin-mediated adhesion of breast cancer cells to fibronectin and collagen IV.
Life Sci. 149: 138-145.
59

142.

Ponnio M, Soukka J, Sillanaukee P, Franck J, Seveus L. 2004. Method for
localization of sialic acid on cell surface and cell interior in peripheral blood: a pilot
study. Microsc Res Tech. 65: 292-294.

143.

Silva BA, Pereira FM, de Jesus JB, Branquinha MH, Santos AL, d'Avila-Levy CM.
2009. Sialoglycoconjugates in Herpetomonas megaseliae: role in the adhesion to
insect host epithelial cells. FEMS Microbiol Lett. 295: 274-280.

144.

Badr HA, Elsayed AI, Ahmed H, Dwek MV, Li CZ, Djansugurova LB. 2013.
Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient
deprivation. Appl Biochem Biotechnol. 171: 963-974.

145.

Hsu KL1, Gildersleeve JC, Mahal LK. 2008. A simple strategy for the creation of
a recombinant lectin microarray. Mol Biosyst. 4: 654-462.

146.

Hernandez JD, Baum LG. 2002. Ah, sweet mystery of death! Galectins and control
of cell fate. Glycobiology. 12: 127R-36R.

147.

Krishnamoorthy L, Mahal LK. 2009. Glycomic analysis: an array of technologies.
ACS Chem Biol. 4: 715-732.

148.

Rey E, Gerbaut L, Lombart C. 1975. Automated method for determination of bound
N-acetylneuraminic acid in serum. Clin Chem. 21: 412-414.

149.

Skoza L, Mohos S. 1976. Stable thiobarbituric acid chromophore with dimethyl
sulphoxide. Application to sialic acid assay in analytical de-O-acetylation. Biochem
J. 159: 457-462.

150.

Hammond KS, Papermaster DS. 1976. Fluorometric assay of sialic acid in the
picomole range: a modification of the thiobarbituric acid assay. Anal Biochem. 74:
292-297.

60

151.

Shukla AK, Schauer R. 1982. Fluorimetric determination of unsubstituted and 9(8)O-acetylated sialic acids in erythrocyte membranes. Hoppe Seylers Z Physiol
Chem. 363: 255-262.

152.

Tzanakakis GN, Syrokou A, Kanakis I, Karamanos NK. 2006. Determination and
distribution of N-acetyl- and N-glycolylneuraminic acids in culture media and cellassociated

glycoconjugates

from

human

malignant

mesothelioma

and

adenocarcinoma cells. Biomed Chromatogr. 20: 434-439.
153.

Hara S, Yamaguchi M, Takemori Y, Nakamura M, Ohkura Y.1986. Highly
sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human
serum and urine and rat serum by reversed-phase liquid chromatography with
fluorescence detection. J Chromatogr. 377: 111-119.

154.

Anumula KR. 1995. Rapid quantitative determination of sialic acids in
glycoproteins by high-performance liquid chromatography with a sensitive
fluorescence detection. Anal Biochem. 230: 24-30.

155.

Hara S, Takemori Y, Yamaguchi M, Nakamura M, Ohkura Y. 1987. Fluorometric
high-performance liquid chromatography of N-acetyl- and N-glycolylneuraminic
acids and its application to their microdetermination in human and animal sera,
glycoproteins, and glycolipids. Anal Biochem. 164: 138-145.

156.

Hara S, Yamaguchi M, Takemori Y, Furuhata K, Ogura H, Nakamura M. 1989.
Determination of mono-O-acetylated N-acetylneuraminic acids in human and rat
sera by fluorometric high-performance liquid chromatography. Anal Biochem. 179:
162-166.
61

157.

Wang D, Zhou X, Wang L, Wang S, Sun XL. 2014. Quantification of free sialic
acid in human plasma through a robust quinoxalinone derivatization and LCMS/MS using isotope-labeled standard calibration. J Chromatogr B Analyt Technol
Biomed Life Sci. 944: 75-81.

158.

Wang L, Wang D, Zhou X, Wu L, Sun XL. 2014. Systematic investigation of
quinoxaline derivatization of sialic acids and their quantitation applicability using
high performance liquid chromatography. RSC Adv. 4: 45797-45803.

159.

Fernando SF, Woonton BW. 2010. Quantitation of N-acetylneuraminic (sialic) acid
in bovine glycomacropeptide (GMP). J Food Compos Anal. 23: 359-366.

160.

Klein A, Diaz S, Ferreira I, Lamblin G, Roussel P, Manzi AE. 1997. New sialic
acids from biological sources identified by a comprehensive and sensitive
approach: liquid chromatography-electrospray ionization-mass spectrometry (LCESI-MS) of SIA quinoxalinones. Glycobiology. 7: 421-432.

161.

Morimoto N, Nakano M, Kinoshita M, Kawabata A, Morita M, Oda Y, Kuroda R,
Kakehi K. 2001. Specific distribution of sialic acids in animal tissues as examined
by LC-ESI-MS after derivatization with 1,2-diamino-4,5-methylenedioxybenzene.
Anal Chem. 73: 5422-5428.

162.

Valianpour F, Abeling NG, Duran M, Huijmans JG, Kulik W. 2004. Quantification
of free sialic acid in urine by HPLC-electrospray tandem mass spectrometry: a tool
for the diagnosis of sialic acid storage disease. Clin Chem. 50: 403-409.

163.

van der Ham M, Prinsen BH, Huijmans JG, Abeling NG, Dorland B, Berger R, de
Koning TJ, de Sain-van der Velden MG. 2007. Quantification of free and total sialic
62

acid excretion by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci.
848: 251-257.
164.

van den Bosch J, Oemardien LF, Srebniak MI, Piraud M, Huijmans JG, Verheijen
FW, Ruijter GJ. 2011. Prenatal screening of sialic acid storage disease and
confirmation in cultured fibroblasts by LC-MS/MS. J Inherit Metab Dis. 34: 10691073.

63

CHAPTER II
QUANTIFICATION OF FREE SIALIC ACID IN HUMAN PLASMA
THROUGH A ROBUST QUINOXALINONE DERIVATIZATION
AND LC-MS/MS USING ISOTOPE-LABELED STANDARD
CALIBRATION FORMULATION

2.1

Introduction
SAs, a family of 9-carbon containing acidic monosaccharides, often terminate the

glycan structures of cell surface and secreted glycoconjugates such as glycoproteins and
glycolipids. SAs are involved in many biological processes like immunological process,
hormonal response, signal transmission, tumor progression, cell adhesion, and protection
mechanisms [1,2]. It has been demonstrated that cancers and cancer stages may be
associated with a significant overrepresentation of SAs on the glycoproteins of cancer cell
surface [3,4]. In addition, SAs exist in both free and conjugated forms in tissues and fluids
such as serum, urine and saliva. Also, it is known that the amount
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of SAs in serum is elevated in cardiovascular diseases, and is a strong predictor of
cardiovascular mortality [5,6]. Therefore, SAs have been considered as a biomarker for
certain types of cancers, cardiovascular diseases and some other diseases.
Because of the great significance of SAs in physiological and clinical applications,
several analytical methods have been developed for quantification of SAs, either free SAs
or SAs released from glycoconjugates in variety of matrices. These include colorimetric
[7,8] and fluorometric [9,10] assays, liquid chromatography coupled with different
detection techniques, such as pulsed amperometric detection [11,12,19], UV [13],
fluorescence [14-20] and mass spectrometry [21-31]. Sample preparation involves either
non-derivatization [11,12,24-29] or derivatization [7-10, 13-23,30,31] before analysis.
Among all these methods, DMB derivatization of SAs combined with HPLC fluorescent
detection [15,16,18-20] and LC-MS/MS detection [22,31] has been the most frequently
used assay due to its high specificity and sensitivity. DMB reacts with α-keto carboxylic
acid, and provides a good response with both fluorescent and mass spectrometric
detections. However, DMB is a highly light sensitive and expensive reagent, which has to
be stored under -20 oC in dark with inert gas. Particular cautions must be taken in the
derivatization procedure. Further, slight variations in the experiment conditions could lead
to a poor reproducibility of the results. In order to overcome these limitations, other
phenyldiamines such as OPD [17] and DDB [23] had been investigated with improved
product stability. In this study, we have checked the chemical and physical properties of
commercial available phenyldiamines and thoroughly investigated a much stable and
inexpensive DAT for SAs derivatization and LC-MS/MS analysis (Figure 6).
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Figure 6:

SA is derivatized with DAT, and then quantified by LC-MS/MS.
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In the FDA guidelines for validation of bioanalytical methods, the same biological
matrix as the matrix in the intended samples should be used for validation purposes
whenever possible. However, the presence of endogenous SAs in plasma causes a difficulty
to construct matrix-matched calibration curve for accurate analysis. To solve this problem,
the most adoptive ways use water [26-30] as matrix or standard addition calibration [21,23]
in SAs quantification. The problem associated with water is that it cannot reflect the
suppression or enhancement of signal caused by co-eluting components in complex
biomatrices, especially with ESI-MS [32,33]. Although standard addition can avoid the
matrix effect, the high background of SAs in biomatrices makes it hard to accurately
calculate a small change from a large value. In this study, we used a stable isotope-labeled
compound 13C3-SA to prepare calibrators and quality control (QC) samples in plasma. In
particular, isotope-labeled compounds possess great similarity in chemical properties with
native compounds, and can provide true relationship between the detection response and
the analyte concentration in a matrix. Overall, a good reproducibility, accuracy and
sensitivity were achieved for free SAs quantification employing UHPLC-MS/MS and
isotope-labeled standard calibration (ILSC) combined with DAT derivatization.
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2.2

Experimental

2.2.1

Materials
N-Acetyl-D-neuraminic acid (SA, 98%) was purchased from Rose Scientific Ltd.

(Edmonton AB, Canada), N-acetyl-D-neuraminic acid-1,2,3-13C3 (13C3-SA, 99%),
ketodeoxynonulosonic acid (KDN, 99%), 3,4-diaminotoluene (DAT, 97%), 1,2-diamino4,5-methylenedioxybenzene (DMB, 98%), 4-bromo-1,2-diaminobenzene (97%), 4-nitroO-phenylenediamine (98%), 2-mercaptoethanol (99%), and sodium hydrosulfite (85%)
were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Acetonitrile (HPLC
grade), methanol (HPLC grade) and acetic acid (ACS grade) were obtained from Fisher
Scientific (Hanover park, IL, USA). Deionized water was generated from Barnstead NanoPURE Water Purification System (Asheville, NC, USA). Human plasma for method
validation was purchased from Innovative Research (Novi, MI, USA). Patient and normal
plasma samples were obtained from Cleveland Clinic (Cleveland, OH, USA).
2.2.2

Stock and work solutions
DAT solution at 10.0 mM was prepared by dissolving DAT reagent in 1.4 M acetic

acid containing 18 mM sodium hydrosulfite and 0.75 M 2-mercaptoethanol. The solution
was kept in refrigerator at 4 oC.
The stock solution of 13C3-SA was prepared in plasma at 1.00 mg/mL, then serially
diluted with plasma to provide work standard solutions at 20.0, 60.0, 200, 600, 2.00 × 103,
6.00 × 103, 2.00 × 104 ng/mL, which were used as the calibrators. These work solutions
for preparation of QC samples were generated in a similar manner at the concentrations of
40.0, 800, and 1.60 × 104 ng/mL. All the 13C3-SA work solutions were aliquoted into 50
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μL per vial. IS work solution was made by dilution of KDN with water to the concentration
of 3.00 × 103 ng/mL. The stock and work solutions were stored at -20 oC until analysis.
2.2.3

Sample preparation
Protein precipitation (PPT) procedure was employed to extract free SA,

13

C3-SA

and IS from plasma samples, including the calibrators, QC standards, blanks and the
unknown samples. After plasma samples were thawed to room temperature, 10 µL of IS
work solution was spiked into each sample of 50 µL except the blanks, in which 10 µL of
water was used. Following a 30 seconds vortex, 150 µL of acetonitrile was added into each
sample, which was vortexed for another 1 min, and then centrifuged at 15,000 g for 5
minutes. Afterwards, 20 μL of supernatant was transferred to another 1.5-mL centrifuge
tube, and mixed with 180 μL DAT solution. The reaction was processed at 80 oC for 40
min, and stopped by cooling in ice water for 5 min. The derivatized samples were then
analyzed using UHPLC-MS/MS as described below.
2.2.4

LC-MS/MS instrumentation and conditions
The UHPLC was a NexeraTM system, consisting of a DGU-20A3R degasser, two

LC-30AD pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A
system controller from Shimadzu (Columbia, MD, USA). The UHPLC system was
interfaced to a Qtrap 5500 mass spectrometer equipped with eletrospray ionization source
from AB SCIEX (Framingham, MA, USA). Data acquisition and processing were
conducted using Analysis 1.6.1 software packaged with Multiquan from AB SCIEX.
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For chromatographic separation, 10 μL of prepared samples were injected onto a
Phenomenex Kinetex C18 column (2.1 × 50 mm, 1.7 m) guarded with a C18
SecurityGuard ultra guard column (Torrance, CA, USA). The column temperature was
maintained at 35 oC during the analysis. The mobile phase was a mixture of water-methanol
(80/20, v/v) at an isocratic flow of 0.3 mL/min.
The MS detection employed positive electrospray ionization, and multiple reaction
monitoring (MRM) for quantification. The quantitative MRM transitions were set at m/z
396 → 253 for SA, 399 → 256 for 13C3-SA, and 355 → 175 for IS; the quality assurance
MRM channels were 396 → 283 for SA and 399 → 286 for

13

C3-SA. The optimal MS

parameters were as follows: Ion Spray Voltage 4500 V, Curtain Gas 30 psi, Nebulizer Gas
30 psi, Heating Gas 40 psi, and Source Temperature 550 oC.
2.2.5

Quantification
Quantification of free SA in plasma was performed using

13

C3-SA as calibration

standard and KDN as IS. SA concentration in unknown sample was calculated according
to the equation: C= Ci × 0.990, where C was the SA concentration; Ci was the value for
the sample obtained directly from the calibration curve, which was constructed using
Multiquan by assaying

13

C3-SA spiked plasma calibrators at seven concentrations in the

range of 20.0 - 2.00 × 104 ng/mL; 0.990 was the conversion factor, calculated by the ratio
of molecular weight of SA to 13C3-SA.
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2.3

Results and discussion

2.3.1

Derivatization of SAs
SAs exist in either free form or conjugated form of glycoproteins and glycolipids.

Among all the SA species, Neu5Ac is the most abundant in human. In this study, we aimed
to develop a sensitive and accurate method for quantification of free Neu5Ac in human
plasma. DMB-based quinoxalinone derivatization has been widely used for SA
quantification [15, 16, 18-20, 22, 31], in which DMB is specialized for α-keto carboxylic
acid with good florescent and MS response. However, DMB is not only instable due to
light and oxygen sensitivity, but also very expensive. In our experiments, we observed that
DMB changed color during a short weighing process, and the chromatographic peak area
of the DMB-SA varied day to day. Therefore, fresh DMB solution needs to be prepared for
each assay, which is very time consuming and often causes analytical variations due to the
high instability of this reagent. In order to overcome this limitation, we have examined
other commercially available compounds having the similar 1,2-diamino-benzene structure
as DMB for SA derivitization and LC-MS/MS analysis (Figure 6). First, commercial free
SA (Neu5Ac) was used for derivitization and optimization study. We found that SA
derivatization with DAT afforded a similar MS intensity as DMB, while 4-bromo-1,2diaminobenzene, and 4-nitro-O-phenylenediamine were about 1/10 and 1/100 of DMB
response, respectively. Therefore, we chose DAT for further optimization of the
derivatization conditions including the concentration, reaction time and temperature. As a
result, DAT concentration higher than 5 mM gave the maximum and constant MS response,
and 80 oC gave the most intense MS peak comparing to 50 oC and 37 oC reaction
temperature. In addition, the highest MS response was achieved after 30 min, and then
71

began to decrease after 80 min. Based on these results, the derivatization of SA was set at
80 oC for 40 min with 10 mM of DAT.
For comparing the stability and reproducibility of DAT and DMB derivatives, the
two freshly prepared reagents were reacted with standard SA solutions at 40 ng/mL
individually on seven consecutive days in our newly developed procedure above and using
the literature condition [16], in which DMB dihydrochloride (7.0 mM) was dissolved in
1.4 M acetic acid containing 18 mM sodium hydrosulfite and 0.75 M 2-mercaptoethanol
and then the reaction was conducted at 50 oC for 2.5 h in dark, respectively. The
derivatization products of each day were stored at -20 oC in dark, and analyzed at the end
of the seventh day all together in one batch using LC-MS/MS. DMB-IS and DAT-IS
samples were prepared on the seventh day, and spiked into each of the corresponding SA
derivatives before LC-MS/MS analysis. As a result (Table III), DMB-SA showed a relative
error from -37% to 88%, while DAT-SA had only -6% to 9% error. Since both reagents
and their products were stabilized by sodium hydrosulfite and 2-mercaptoethanol, the
larger variation of DMB-SA may be due to its high instability with light and oxygen, which
makes it difficult to handle in a repeatable manner. Furthermore, another advantage of DAT
was the low price, thousands of times cheaper than DMB. In fact, the high cost of DMB is
a problem considering that its reagent solution needs to be prepared freshly each time.
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TABLE III:

DMB-SA (ng/mL)
RE %

DAT-SA (ng/mL)
RE %

Spiked conc.

Reproducibility of DMB and DAT derivatization (n = 3)
1st day

2ed day

3rd day

4th day

-37

16

9

-2

40.0

50.3

75.2

25.3

40.0

37.7

42.8

43.6

26
-6

88

7

73

5th day

6th day

46.3

32.0

57.6

39.1

38.7

40.7

-20

-3

7th day

40.0

44

0

2

0

40.0

2.3.2

Isotope-labeled standard calibration (ILSC)
According to the FDA guidelines for validation of bioanalytical methods, the

calibrators and QCs for analysis should be prepared using the same types of matrices as
samples to be measured [34]. It has been strongly recommended to use matrix-matched
calibration for quantification assays employing LC-MS or LC-MS/MS due to such a matrix
effect that some of the matrix components could suppress or enhance the mass
spectrometry signals of the analytes or IS [32]. An HPLC-ESI-MS/MS method developed
for the quantification of free SA in urine employed creatinine-adjusted urine as blank
matrix for calibration preparation, which had a limit of detection of 927 ng/mL [24]. In
order to achieve highly sensitive and accurate quantification, we used

C3-SA as a

13

surrogate standard to generate calibration curves and QC samples. Since 13C3-SA possesses
the same chemical structure and properties as SA, and they have identical stability,
derivatization efficiency, chromatographic retention, and MS response and fragmentation
pattern, the specific and sensitive detection of them could be obtained by mass
spectrometry in MRM mode upon their difference in m/z values.
2.3.3

Optimization of LC-MS/MS conditions
Chromatographic conditions were optimized to obtain higher specificity,

sensitivity, and shorter analysis time. Various mobile phases including different
percentages of methanol in water and acetonitrile in water with or without additives were
evaluated, and 20% methanol at 0.3 ml/min provided the optimal results. It was found that
the LC-MS/MS signal from 13C3-SA was at least two times higher with methanol-water as
mobile phase than acetonitrile-water. Addition of formic acid or ammonium acetate into
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the mobile phase substantially reduced the peak intensity. Under this selected
chromatographic conditions, the retention times for SA, 13C3-SA and IS were 3.6 min, 3.6
min, and 2.4 min, respectively. The total run time was 4.2 min, which was the shortest
analysis time for quantification of free SA reported so far [11-31].
The product ion scan spectra of [M+H]+ precursors from the derivatized SA, 13C3SA and IS are illustrated in Figure 7 A-C; the proposed fragmentation pathway for SA is
shown in Figure 8. The calibration standard,

13

C3-SA, had three relatively abundant

fragments with m/z 256, 286, and 381. However, m/z 256 was found to have the highest
signal to noise ratio (S/N) at LLOQ concentration than the other two fragment ions. After
optimization and evaluation, we selected transitions of m/z 396 → 253 for SA, 399 → 256
for 13C3-SA, and 355 → 175 for IS as the MRM channels for quantification. The transitions
of 396 → 283 for SA and 399 → 286 for 13C3-SA were also monitored during LC-MS/MS
analysis for quality assurance.
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Figure 7:

Product ion spectra of [M+H]+ precursors. (A) DAT-SA, (B) DAT-13C3-SA,

(C) DAT-IS.
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Figure 8:

Proposed fragmentation pathway of [DAT-SA+H] +.
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2.3.4

Free SA extraction from plasma
There are both free SA and conjugated SA in human plasma, all together called

total SA, and free SA accounts a small portion of total SA. Therefore, it is critical to
effectively extract free SA from the plasma and separate the conjugated forms from the
extractants. In this study, three different extraction methods were examined, including PPT
with acetonitrile and methanol, and dialysis with 3 kD centrifugal filter (Amicon® Ultra,
catalog number R1NA37692). Methanol and acetonitrile were often used for PPT with
human fluid to obtain free SA [28,29]. In our study, free SA peaks in plasma samples after
methanol-PPT were about 30 times higher than those after acetonitrile-PPT (Table IV).
This may be attributed to the incomplete removal of conjugated SA from plasma. To test
this hypothesis, the supernatants of both methanol- and acetonitrile-PPT samples were
dried with nitrogen at 37 oC, and the residues were reconstituted into the same volume of
water. Then 20 μL of each sample was subjected to 15% SDS-PAGE analysis. As shown
in Figure 9, trace proteins exist in methanol-PPT samples, while no protein bands were
observed in acetonitrile-PPT samples, indicating a complete remove of proteins. Therefore,
acetonitrile-PPT was used to remove the conjugated SA and obtain the free SA from
plasma in our study.
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TABLE IV:

Area (counts)

Figure 9:

Dialysis

SA peak areas from different sample preparations (n = 3).

(6.31 ± 0.42) × 105

Methanol-PPT

(1.69 ± 0.13) × 107

Acetonitrile-PPT

(6.02 ± 0.24) × 105

Non-extraction

(2.54 ± 0.21) × 108

SDS-PAGE chromatograms of plasma and its PPT samples: (A) Protein ladder, (B) human plasma, (C) plasma samples

precipitated with methanol, (D) plasma samples precipitated with acetonitrile.
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2.3.5

Method validation

2.3.5.1 Linearity of calibration
Calibration curves were constructed using seven calibrators prepared from pooled
plasma spiked with 13C3-SA at concentration range of 20.0 - 2.00 × 104 ng/mL and IS at
3.00 × 103 ng/mL. A typical equation obtained from weighted (1/x) linear regression was
y = 9.27 × 10-4 x - 3.13 × 10-4, where y was the peak area ratio of 13C3- SA to IS, and x
was the concentration of 13C3- SA in spiked plasma. The correlation coefficient (r) was at
least 0.999, indicating that the calibration was highly linear within the concentration range.
2.3.5.2 Specificity, sensitivity, and LLOQ
The specificity and sensitivity were evaluated by analyzing LLOQ samples
prepared from six individual lots of plasma and the blanks (no

13

C3-SA or IS) from the

same lots of plasma. As shown in Figure 10, no significant interference was observed in
the retention time windows of

C3-SA and IS. The coefficient of variation (CV) and

13

relative error (RE) for measurement of LLOQ samples were 6% and -1%, respectively,
which indicated that this assay was sensitive enough to quantify SA at 20 ng/mL.
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Figure 10:

Representative MRM chromatograms of native/labeled SA and IS. (A) A

pooled blank plasma sample, (B) a pooled plasma sample spiked with 13C3-SA at the LLOQ
of 20.0 ng/mL and IS, (C) a plasma sample from a patient spiked with IS.
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2.3.5.3 Extraction recovery and matrix effect
The extraction recovery of free SA from plasma using acetonitrile-PPT was
determined by comparing chromatographic peak areas from two sets of plasma samples.
The first set was spiked with 13C3-SA at three QC levels and IS before PPT, and the second
set was spiked at the corresponding concentrations after PPT. The absolute extraction
recovery of 13C3-SA was over 70%, and the IS-normalized recovery was nearly 100%. To
evaluate the matrix effect, the peak areas obtained from the second set of extraction
recovery samples were compared with those of

C3-SA and IS prepared in water at

13

equivalent concentrations. Both the absolute and IS-normalized matrix effect were close to
100%, which meant the matrix effect was negligible in this study.
2.3.5.4 Precision and accuracy
The intra-assay and inter-assay precision and accuracy were studied by determining
the QC samples at three concentrations in five replicates, and the results are listed in Table
V. The CV was within 5% and the RE was in the range of -5 to 5%, which well fulfilled
the FDA criteria for bioanalysis [34].
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TABLE V: Intra- and inter-assay precision and accuracy for measurement of spiked 13C3-SA in plasma (n=5)
QC
Low
Mid

Spiked conc.
(ng/mL)

Mean ± SD

40.0

39.9 ± 1.4

800

High
1.60 × 104
a
CV % = (SD/Mean) × 100%
b

(ng/mL)

839 ± 17

Intra-assay

Precision

Accuracy

Mean ± SD

3

-1

38.1 ± 1.8

(CV %)
2

(1.67 ± 0.03) × 104 2

a

(RE %)
5

4

RE % = [(Mean – Spiked)/Spiked] × 100%

84

b

(ng/mL)

811 ± 29

(1.65 ± 0.06) × 104

Inter-assay

Precision

Accuracy

5

-5

(CV %)
4

4

(RE %)
1

3

2.3.5.5 Stability
The stability of SA-DAT derivatives in human plasma was assessed by analyzing
five replicates of low and high QC samples undergoing different storage conditions pre and
post sample preparations. As shown in Table VI, there was essentially no change with 13C3SA in the QC samples kept at -80 oC for two weeks, or room temperature (RT) for 8 hours.
It was also stable in the autosampler at 4 oC for 10 hours post sample preparation.
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TABLE VI:

Stability of 13C3-SA in plasma pre and post sample preparation (n = 5)

Storage condition
2 weeks at -80 oC

QC
Low

Spiked conc.

Mean ± SD

40.0

41.1 ± 2.8

103

42.3 ± 1.5

106

(ng/mL)

High 1.60 × 104

(1.60 ± 0.06) × 104

3 freeze (-80 oC)-thaw Low 40.0
(RT) cycles
High 1.60 × 104
8 h at RT
10 h at 4 oC post
preparation

(ng/mL)

(1.70 ± 0.06) ×104

Stability
(Recovery %) a

100

106

Low

40.0

39.8 ± 1.9

100

Low

40.0

42.6 ± 1.3

107

High 1.60 × 104

(1.68 ± 0.06) × 104

High 1.60 × 104
a
Recovery % = Mean/Spiked × 100%

(1.75 ± 0.04) × 104

86

105
110

2.3.6

Assay application
This validated method was applied to determine free SA in plasma samples from

30 patients and 6 normal people. The free SA concentration in patient samples ranged from
419 to 862 ng/mL with an average of 651 ng/mL, while in normal people, the free SA
concentration ranged from 280 to 354 ng/mL with an average 323 ng/mL (Figure 11). To
our best knowledge, this is the first study to quantify free SA in human plasma using LCMS/MS. In order to make statistical assumption, measurement of a large number of
samples needs to be carried out in the future.
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Figure 11:

Free SA in plasma samples from 30 patients and 6 healthy people.
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2.4

Conclusion
We developed a LC-MS/MS method with isotope-labeled standard calibration for

sensitive quantification of free SA in human plasma, in which free SA,

13

C3-SA as

calibration standard, and KDN as IS were derivatized with a stable and inexpensive DAT.
Briefly, plasma samples were first mixed with acetonitrile to precipitate proteins and
separate free SA from conjugated SA. Then the free SA, 13C3-SA, and IS were derivatized
with DAT. The derivatives were injected onto a Phenomenex Kinetex C18 column for
separation using a mixture of water-methanol (80/20, v/v) as the mobile phase at an
isocratic flow of 0.3 mL/min. The detection was performed on an AB Sciex Qtrap 5500
mass spectrometer with positive ESI employing multiple reaction monitoring (MRM)
mode. Overall, we have demonstrated a robust derivatization of SA with DAT, which is
cost-effective and provides a stable product of SA with high MS response. We have
achieved a LLOQ of 20 ng/mL and a total run time of 4.2 min, which is the most sensitive
and fast measurement for free SA in biomatrices. This assay was validated for linearity,
precision and accuracy, and stability following the FDA guidance for bioanalytical method
validation. The method was successfully applied to quantification of free SA in human
plasma and is expected to be applied for accurate quantification of SA for both biological
research and clinical applications.
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CHAPTER III

GLOBALLY PROFILING SIALYLATION STATUS OF
MACROPHAGES UPON STATIN TREATMENT

3.1

Introduction
SAs ubiquitously distribute on the cell surfaces and locate on the outermost position

of the glycan structures in a variety of glycoconjugates [1-3]. This particularly spatial
orientation and great abundance endows SAs with important functions in a wide range of
physiological and pathological processes, such as immunological process, cell adhesion
and infection [3, 4]. SAs expressed on immune cells are closely related to their activities.
An early study found that macrophages form rosettes with normal sheep erythrocytes but
not the one after sialidase pretreatment [5]. Also, guinea pig peritoneal macrophages
pretreated with sialidase bound more 125I-IgG than non-treated cells [6]. Further, sialidase
treatment can substantially enhance the capacity of resting B cells to stimulate the
proliferation of allogeneic and antigen specific syngeneic T cells [7-9]. All these studies
reveal a fact that cell surface SAs on immune cells are involved in a diverse regulation of
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immune cell interactions and play important roles related to both physiological and
pathological processes.
So far, a number of studies have been performed on the SA binding proteins in the
immune system. The SAs recognizing proteins are categorized to the family of siglecs,
which represents SAs recognizing Ig superfamily lectins. The founding members of the
siglec family include sialoadhesin (siglec-1), a macrophage adhesion molecule [10-12];
CD22 (siglec-2), a B-cell inhibitory receptor [13]; CD33 (siglec-3), a marker of myeloid
cells [14]; and myelin associated glycoprotein (MAG or siglec-4), expressed by
oligodendrocytes and Schwann cells in the nervous system [15]. Despite the extensive
studies on the SAs binding proteins in the immune system, the SAs profile of immune cells
themselves was largely overlooked for decades. In particular, the sialylation status related
to the linkages and the amount of SAs on the immune cell surface is less known so far.
It was reported that cell surface sialylation pattern changes during apoptosis in
several cell types, including colon carcinomas and thymocytes [16, 17]. Also, cell surface
sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell
death [18]. A recent study found that decreasing of SA residues on the surface of apoptotic
lymphocytes was recognized as an “Eat-Me” signal [19]. In addition, it was reported that
ST6Gal-I regulates macrophage apoptosis via α-2,6 sialylation of the TNFR1 death
receptor [20].
Statin drugs, as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, are widely used in the treatment of hypercholesterolemia for more than a
decade. In addition to their lipid-lowering effect, convincing evidence demonstrated that
statins have a wide effect on macrophages. For example, statins were found to reduce the
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cell numbers of macrophages in vivo and in vitro [21-23], and one mechanism could be
attributed to its apoptosis induction effect on macrophages at even low dosages [22, 23].
Moreover, the immunomodulatory roles of statin have been studied in macrophages on the
cytokine and corresponding protein levels, such as inhibiting inducible nitric oxide
synthase [24, 25], augmenting LPS-induced proinflammatory responses [26], and inducing
Th2 cytokines secretion while suppressing Th1 cytokines production [27]. Although detail
mechanisms have been elucidated in each study, most of these pleiotropic effects are
mediated by the inhibition of the synthesis of isoprenoid intermediates such as
farnesylpyrophosphate and geranylgeranylpyrophosphate, which are essential for many
cellular functions like differentiation and proliferation [28].
In this study, we systematically investigated the sialylation status of macrophages
in the normal culture condition and after atorvastation treatment. In particular, we globally
profiled SAs linkages and levels of respective SA forms on the cell surface by confocal
microscopy and flow cytometry with SA-specific lectins SNA and MAA. Further, free,
conjugated, and total SAs in the cell culture medium and total SAs in the cells were
quantified in both normal and statin-treated conditions by a newly developed LC-MS/MS
method. The combination of confocal microscopy, flow cytometry, and LC-MS/MS
provides the first time of global investigation of the cellular sialylation status of
macrophages in the entire cell culture system, which will contribute to a better
understanding of the physiological and pathological roles of SAs in macrophages and in
the immune system as well.
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3.2

Materials and methods

3.2.1

Materials
FITC labeled MAA lectin was purchased from bioWORLD (Dublin, OH, USA).

FITC labeled SNA lectin was provided by Vector Laboratories (Burlingame, CA, USA).
Alexa Fluor 488 labeled Annexin V, APC labeled Annexin V, and ProLong Gold Antifade
Mountant were obtained from Life Technologies (Grand Island, NY, USA). Atorvastatin
was purchased from A Chem Tek Inc. (Worcester, MA, USA). N-acetyl-D-neuraminic acid
(SA, 98%) was supplied by Rose Scientific Ltd. (Edmonton AB, Canada). N-acetyl-Dneuraminic acid-1,2,3-13C3 (13C3-SA, 99%), 4',6-diamidino-2-phenylindole (DAPI),
propidium iodide (PI), RIPA buffer, protease inhibitor cocktail, rabbit anti-ST6Gal-I
antibody, rabbit anti-ST6GalNAc-II antibody, rabbit anti-ST6GalNAc-VI antibody, and
goat anti-rabbit IgG-peroxidase antibody were purchased from Sigma-Aldrich Inc. (St.
Louis, MO, USA). Acetonitrile (HPLC grade), paraformaldehyde (PFA, 16% w/v), and
acetic acid (ACS grade) were obtained from Fisher Scientific (Hanover park, IL, USA).
3.2.2

Apparatus
Flow cytometry was performed on a FACSCanto Ⅱ system consisting of a blue

and a red laser, operated through BD FACSDiva software (BD Bioscience, Mountain
View, CA, USA). Images were acquired at a 60 × magnification using a Nikon A1Rsi
confocal microscope, and data analysis was performed using NIS-Elements software
(Nikon Instruments Inc., Melville, NY, USA). LC-MS/MS quantification was carried out
by a Nexera liquid chromatography system (Shimadzu, Columbia, MD, USA) interfaced
to a Qtrap 5500 mass spectrometer equipped with eletrospray ionization source (AB
98

SCIEX, Framingham, MA, USA), and the data acquisition and processing were conducted
using Analysis 1.6.1 software.
3.2.3

Cell culture and stimulation
Raw 264.7 cells, obtained from American Type Culture Collection, were cultured

in Dulbecco’s modified Eagle’s medium (DMEM, Cleveland Clinic Core Facility,
Cleveland, OH, USA) supplemented with 10% fetal bovine serum (FBS, Atlanta
Biologicals, Flowery branch, GA, USA) and 1% penicillin/streptomycin (Cleveland Clinic
Core Facility, Cleveland, OH, USA) in a humidified atmosphere containing 5% CO 2 at 37
C. In order to quantify free SAs, FBS was removed from culture medium before adding

o

drug. For atorvastatin simulation, cells were seeded in 6-well plates for overnight, followed
by atorvastatin treatment at different concentrations and incubation times. The media
without FBS were collected and centrifuged at 15,000 g for 5 min. The supernatants were
stored at -20 oC until use. Cells were analyzed by flow cytometry, confocal microscopy, or
LC-MS/MS.
3.2.4

Flow cytometric analysis
For determination of cell surface SA, cells were treated with atorvastatin (or

vehicle) for 24h. The cells were harvested and washed 3 times with cold phosphate buffered
saline (PBS), and then suspended in 50 μL MAA (10 μg/mL) or SNA (20 μg/mL), and 5
μL PI (1000 μg/mL). After incubation for 30 min at room temperature, cells were washed
with cold PBS for 3 times and re-suspended in the same buffer for flow analysis. A
minimum of 20,000 cells were measured each time.
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Cell apoptosis study was performed by staining cells with Annexin V and PI using
the dead cell apoptosis kit (Life technologies, Grand Island, NY, USA). Briefly, cells
treated with or without 20 μM atorvastatin for 14, 24, and 38 h were collected and washed
3 times with cold PBS, and then resuspended in 100 μL of 1 × binding buffer provided by
the manufacturer. Annexin V (5 μL) and PI (1 μL) were added to the cell suspension and
incubated at room temperature for 15 min. After incubation, 400 μL of 1 × binding buffer
was added to each vial and cells were analyzed immediately with flow cytometry.
3.2.5

Confocal microscopy
Cells were seeded on cover slip in 6-well plate for overnight, and then treated with

20 μM atorvastatin (or vehicle) for 24 h. After incubation, cells on cover slip were washed
for 3 times with cold PBS, and fixed with 4% PFA for 10 min. Excess PFA was removed
by another 3 times wash with cold PBS. Then cells were stained with MAA-FITC (10
μg/mL) or SNA-FITC (20 μg/mL) for 30 min, followed by 1 min DAPI stain. Unbound
lectin was washed off with cold PBS and cover glasses were mounted on ProLong Gold
Antifade reagent.
3.2.6

LC-MS/MS analysis
SA and IS were separated by a Primesep D column (2.1 × 100mm, 5 μm; SIELC

Technologies, Prospect Heights, IL, USA) with a binary linear gradient elution, in which
phase A was deionized water containing 10 mM ammonium formate and 0.1% formic acid,
and phase B was a mixture of 90% acetonitrile, 10% water, 3 mM ammonium formate, and
0.04% formic acid. The gradient program started at 10% B and maintained for 1 min, and
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then changed linearly to 100% B in 3 min and maintained for 2 min. In order to equilibrate
the column, the gradient sharply dropped to 10% B in 0.1 min and kept for 2.9 min. The
total run time was 9 min for each sample. The MS detection was carried out in negative
electrospray ionization and MRM mode. The quantitative MRM transitions were set at m/z
308 → 87 for SA, and 311 → 90 for IS. The quality assurance MRM channel for SA was
set at m/z 308 → 170.

3.2.6.1 Method validation sample preparation
SA calibration standards were prepared in DMEM at concentrations of 2.00, 6.00,
20.0, 60.0, 200, 600, 2.00×103 ng/mL. The QC samples were prepared in the same manner
at low, mid and high concentrations of 4.00, 100, and 1.60×10 3 ng/mL. IS was prepared in
DMEM at the concentration of 2.00×103 ng/mL. For the sample preparation, 5 μL IS was
mixed together with 95 μL calibration standards or QC samples, and 5 μL of the mixture
was subjected to the LC-MS/MS analysis.
3.2.6.2 Cell culture sample preparation
Free SA in the medium was quantified by spiking 95 μL of culture medium with 5
μL of IS, and then 5 μL of the mixture was injection to LC-MS/MS system. In order to
determine total SA in culture medium, the sample was first hydrolyzed with 2 M acetic
acid (1:1) at 80 oC for 90 min, and then 5 μL of the IS was added to 95 μL of the lysate
before analysis. For quantification of total SA of the cell, the sample at a density of 1×10 6
cells/mL was untrosonicated to obtain homogeneous mixture. Then follow the procedure
of total SA quantification in culture medium.
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3.2.7

Western blot
Cells were washed twice with ice-cold PBS and lysed with RIPA buffer on ice for

5 min. The cell lysates were collected and clarified by centrifugation at 15,000 g at 4 oC
for 10 min. Protein concentrations were measured by the Bradford method using a protein
assay kit (Bio-Rad, Hercules, CA, USA). Proteins (30 μg/sample) were fractionated on
SDS-15% polyacrylamide gels and transferred to polyvinylidene difluoride membrane.
The membranes were blocked with 5% nonfat milk in Tri-buffered saline containing 0.05%
Tween 20 (TBS-T) for 1 h at room temperature, and then probed with primary antibodies
in TBS-T buffer with 5% nonfat milk at 4 oC overnight. The membranes were washed 3
times with TBS-T buffer, followed by incubation with secondary antibody for 1 h at room
temperature. Antibody detection was accomplished by using the ECL Prime kit (Pierce)
with the LI-COR Odyssey Fc imaging system.
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3.3

Results

3.3.1

Cell surface SAs analyzed by confocal microscopy and flow cytometry
SAs are commonly found α-2,3 and α-2,6 linked to galactose residue on the cell

surface [29]. In our study, we first performed confocal microscopy and flow cytometry
analysis to distinctively measure SAs with different linkages on the macrophage surfaces
by using MAA-FITC and SNA-FITC, which specifically bind to α-2,3 and α-2,6 linked
SAs, respectively. From the confocal microscopy study, MAA-FITC showed very strong
binding compared to SNA-FITC on the cell surface of macrophages cultured under the
normal condition (Figure 12A). After cells were treated with atorvastatin for 24 h, MAAFITC binding remained unchanged (Figure 12B), while SNA-FITC binding increased
dramatically (Figure 12B).
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Figure 12:

Confocal microscopy analysis of cell surface SA. (A): Raw 264.7 cells at

the normal culture condition were stained with MAA-FITC (10 μg/mL) and SNA-FITC
(20 μg/mL), respectively. DAPI was used to stain nuclei. (B): Raw 264.7 cells were treated
with 20 μM atorvastatin for 24 h followed by staining with lectins and DAPI. The scale bar
represents 10 μm. (C): The fluorescent intensity of the confocal images was analyzed by
ImageJ obtained from National Institutes of Health (n = 4).
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Next, the lectin-labeled cells were analyzed by flow cytometry. The similar binding
pattern was observed from macrophages under the normal and atorvastatin conditions. In
particular, SNA-FITC binding for macrophages was significantly increased upon
atorvastatin treatment (Figure 13). The dot plots indicated that approximately 80% of the
cells were MAA positive and 10% were SNA positive in the normal condition (Figure
13A). After 24 h atorvastatin treatment, no apparent change in MAA-FITC labeling was
observed, but peak shift was apparently found from SNA-FITC labeled cells (Figure 13B).
The dot plots showed the total ratio of SNA positive cells increased about 3 times as
compared with the untreated cells. Further, the lectin stainings were performed on
permeabilized cells, and the peak shift was found in SNA-FITC labeled cells in both
permeabilized and non-permeabilized conditions with atorvastatin treatment, while no
significant change in MAA-FITC labeled cells were observed. Interestingly, large peak
shift was found in SNA-FITC labeled cells with permeabilization independent on
atorvastatin treatment (Figure 14). These results indicate that 2,6 linked SA increased both
on the cell surfaces and inside the cells.
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Figure 13:

Determination of cell surface SAs by flow cytometry. (A): Raw 264.7 cells

at normal condition were stained with MAA-FITC (10 μg/mL) and SNA-FITC (20 μg/mL),
respectively. PI staining was used to distinguish living cells and dead cells. (B): Raw 264.7
cells were treated with 20 μM atorvastatin for 24 h then stained with lectins and PI. Data
is a representative of at least three independent experiments.
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Figure 14:

Comparison of SAs level after cell permeabilization. Atorvastatin +: Cells

were treated with 20 μM atorvastatin for 24 h. Atorvastatin -: Cells were incubated with
vehicle for 24 h. Permeabilization +: Cells were fixed with 4% PFA, followed by
permeabilization with 0.2% triton X-100, and then labeled with lectins. Permeabilization : Cells were fixed with 4% PFA, and then labeled with lectins. (A): Raw 264.7 cells at
different conditions were labeled with MAA-FITC (10 μg/mL). (B): Raw 264.7 cells at
different conditions were labeled with SNA-FITC (20 μg/mL).
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3.3.2

Comparison of SNA and Annexin V staining
It is known that statins stimulate apoptotic cell death in several types of immune

cells, such as macrophages [22, 23]. Annexin V specifically binds to membrane
phosphatidylserine and has been widely used for early apoptosis detection [30, 31]. In our
study above, a significant SNA-FITC staining increase was observed for atorvastatin
treated cells compared with MAA-FITC staining (Figure 12B and 13B). Therefore, we
compared the SNA labeling and Annexin V labeling of the cells treated with 20 μM
atorvastatin for 14, 24, and 38 h, respectively. As shown in Figure 15A, both SNA and
Annexin V positive cells increased dramatically with the incubation time prolonged.
Briefly, in the control sample (0 h), the SNA positive cell ratio was only 9.4%, which
included both PI positive and negative cells, while the SNA positive cells increased to
23.5%, 33.6% and 41.3% when the cells were incubated with atorvastatin for 14, 24 and
38 h, respectively. Meanwhile, Annexin V positive cells increased in the same timedependent manner as SNA labeling. However, the change scale of Annexin V labeling was
smaller compared with SNA labeling. These results are further supported by the SNA and
Annexin V co-stainings of the cells (Figure 15 B). All these results indicated that α-2,6
linked SAs were highly expressed on the surface of cells undergoing apoptosis and thus
may be used as a marker for apoptosis detection as well. Further study to prove the
correlation of macrophage apoptosis and α-2,6 linked SAs status is much deserved.
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Figure 15:

Comparison of SNA and Annexin V labeling of Raw 264.7 cells after cells

incubated with atorvastatin. (A): Cells were treated with or without atorvastatin (20 μM)
for 14, 24 and 38 h, and then labeled with SNA or Annexin V. Both PI positive and negative
cells are included here. Values represent means and standard deviations from three
independent experiments (n=3). (B): Cells were treated with atorvastatin (or vehicle) for
24h, and then co-stained with SNA-FITC and Annexin V-APC.
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3.3.3

LC-MS/MS quantification of SAs in the culture media and cell lysates

3.3.3.1 Method validation
In this study, we developed a new LC-MS/MS method to quantitatively examine
the free SAs and conjugated SAs levels in the cell culture media, and the total SAs in the
cell lysates upon cell treated with atorvastatin. The mass spectra for both SA and 13C3-SA
(internal standard, IS) were obtained in negative electrospray ionization (Figure 16). The
MS detection was carried out in negative electrospray ionization and multiple reaction
monitoring (MRM) mode. The representative chromatograms for the LLOQ sample and a
sample obtained from cells are shown in Figure 17. The calibration range was obtained
from 2.00 to 2.00 × 103 ng/mL and the LLOQ was 2.00 ng/mL. Importantly, the large
calibration range and low LLOQ facilitate the determination of small amount of free SAs
in the cell culture medium and total SAs in the cell lysate. This method was validated for
matrix effect (Table VII), precision and accuracy (Table VIII), and stability (Table IX).

110

Figure 16:

The mass spectra of SA and 13C3-SA (IS). SA or 13C3-SA standard solution

at a concentration of 100 ng/mL in water was infused into mass spectrometer at a speed of
10 μL/min. After ionization and fragmentation, the spectra were obtained from a product
ion scan mode from m/z 50 to m/z 350. The fragment ions of m/z 87 for SA and m/z 90 for
C3-SA were selected for quantification. Fragment of m/z 170 for SA was used for quality

13

assurance.
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Figure 17:

Representative MRM chromatograms of SA and 13C3-SA. (A) a culture free

DMEM medium sample, (B) a culture free DMEM medium sample spiked with SA at the
LLOQ of 2.0 ng/mL and 13C3-SA at 100 ng/mL, (C) a cell lysate sample from a cell density
of 1×106 cells/mL spiked with 13C3-SA at 100 ng/mL.
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TABLE VII: Matrix effect of SA spiked in cell culture medium (n=4)
Spiked SA (ng/mL)
4.00
100

Peak Area (counts)
SA in Medium

1.72 × 104
4.07 × 105

SA in Water

1.72 × 104
4.08 × 105

Matrix Effect a
100%
100%

1.60 × 103
6.92 × 106
6.59 × 106
105%
a
Matrix Effect = mean peak area of SA in culture medium / mean peak area ratio of SA in water
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TABLE VIII: Intra- and inter-assay precision and accuracy for measurement of spiked SA in cell culture medium (n=5)
Spiked SA
(ng/mL)
4.00
100

Intra-assay

Mean ± SD

Precision

Accuracy

Mean ± SD

Precision

Accuracy

3.90 ± 0.08

2

-2

4.00 ± 0.08

2

0

(ng/mL)

97.9 ± 2.8

1.60 × 103
(1.65 ± 0.04) × 103
a
CV % = (SD/Mean) × 100%
b

Inter-assay

(CV %)
3

2

a

(RE %)
-2

b

(ng/mL)

96.3 ± 2.2

3

(1.61 ± 0.02) × 103

RE % = [(Mean - Spiked)/Spiked] × 100
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(CV %)
2

1

(RE %)
-4

1

TABLE IX:
Storage Condition
8 h at RTb

Stability of SA in cell culture medium (n = 5)

Spiked SA (ng/mL)

Mean ± SD (ng/mL)

Stability (Recovery % )a

4.00

3.95 ± 0.09

98.8

1.60 × 103

(1.60 ± 0.01) × 103

100

1.60 × 103

(1.67 ± 0.06) × 103
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1.60 × 103

(1.60 ± 0.03) × 103

100

1.60 × 103
a
Recovery % = Mean/Spiked × 100%

(1.60 ± 0.04) × 103

100

24 h at 4 oC
3 freeze-thaw (RT)
cycles
72h at 37 oC

b

4.00
4.00
4.00

3.96 ± 0.13
4.07 ± 0.20
4.04 ± 0.17

RT: room temperature
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3.3.3.2 SAs concentration in cell culture samples
The validated method was successfully used for quantifying the free SAs and
conjugated SAs in the cell culture media, and the total SAs in the cell lysates, which would
indicate SAs releasing and synthesis fact related to cell function alteration (Figure 18).
First, the concentrations of free SAs in the cell culture media under the normal culture
condition and incubation with atorvastatin for 24 h were measured by LC-MS/MS. As a
result, free SAs in the normal culture condition were 6.31 ± 0.45 ng/mL and no apparent
change was observed after atorvastatin treatment. Meanwhile, the total SAs and conjugated
SAs in the cell culture media were 73.2 ± 3.3 ng/mL and 66.9 ± 3.6 ng/mL under the normal
condition and slightly increased to 80.9 ± 7.1 ng/mL and 74.3 ± 7.0 ng/mL, respectively,
after incubation with 20 μM atorvastatin. Next, the total cellular SAs, including on the cell
surfaces and inside the cells were measured by LC-MS/MS after releasing SAs from the
cell lysates. As a result, the cellular SAs concentration was 369 ± 29 ng/mL at a density of
1×106 cells/mL under the normal culture condition, while it increased to 567 ± 25, 775 ±
32 and 1080 ± 50 ng/mL corresponding to 5, 10 and 20 μM of atorvastatin used,
respectively.
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atorvastatin

Figure 18:

SAs concentrations in the cell culture system. Cells were treated with

vehicle (0 μM) or atorvastatin at 5, 10, and 20 μM for 24 h. Then free SAs in the medium
were quantified by LC-MS/MS directly. The medium was hydrolyzed with acetic acid
followed by LC-MS/MS analysis to determine the total SAs. Conjugated SAs in the
medium were calculated by subtracting the free form from total SAs. In order to quantify
total SAs of the cell, cells were first ultrasonicated to obtain homogeneous mixture,
followed by acid hydrolysis and LC-MS/MS analysis. MF, medium free SA; MC, medium
conjugated SA; MT, medium total SA; CT, cell total SA. The results were repeated in at
least three independent experiments. Data is a representative from one experiment with
three samples (n=3).
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3.3.4

Western blot analysis of selected α-2,6 sialyltransferase level
The LC-MS/MS results of increased cellular SAs may be in accordance with the

increase of α-2,6 linked SAs on the cell surface after atorvastatin treatment as observed by
flow cytometry and confocal microscopy above. Therefore, we further performed western
blot analysis of the cellular α-2,6 sialyltransferases in normal and statin conditions. These
sialyltransferases are grouped into two families according to the carbohydrate linkages they
synthesize, including ST6Gal I and II, and ST6GalNAc I-VI [32]. ST6Gal-I for N-glycan,
ST6GalNAc-II for O-glycan, and ST6GalNAc-VI for glycolipids have been investigated
on immune cells [32-34]. As shown in Figure 19, ST6GalNAc-II was found highly
increased, ST6GalNAc-VI no apparent change, while ST6Gal-I decreased upon
atorvastatin treatment (with 20 μM for 24 h). Therefore, the elevation of ST6GalNAc-II
may contribute to the increased cellular SAs and α-2,6 linked SAs on the cell surface after
atorvastatin treatment. There may be other sialyltransferases related to the increase of α2,6 linked SAs as well, which deserve a further study in future.
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Figure 19:

Western blot analysis of Raw 264.7 cells sialyltransferases upon

atorvastatin treatment. Raw cells were incubated with 20 μM atorvastatin (or vehicle) for
24 h, and the ST6Gal-I, ST6GalNAc-II and ST6GalNAc-VI were determined by western
blot analysis using rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody, and
rabbit anti-ST6GalNAc-VI antibody, respectively.
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3.4

Discussion
Macrophages play very important roles in the immune system related to both

physiological and pathological pathways. SAs terminate most glycans on the cell surface
and are involved in variety of physiological and pathological activities of immune cells. In
this study, we used Raw 264.7 macrophages to comprehensively profile the sialylation
status in the cell culture system including cell surface SAs levels and their linkages,
secreted free, conjugated and total SAs in the culture medium and total SAs in the cells as
well. First, cell surface SAs were determined by confocal microscopy and flow cytometry
by using SNA and MAA labeling. As a result, α-2,3 linked SAs were found to be
predominant on the Raw 264.7 macrophage surfaces, while α-2,6 linked SAs were less
observed under the normal culture condition (Figure 12A). After cells were treated with
atorvastatin for 24 h, α-2,3 linked SAs were unchanged, however, α-2,6 linked SAs
increased significantly on cell surface (Figure 12B, Figure 13B). The wide distribution of
α-2,3 linked SAs may be associated with the cell-cell interaction and signaling transduction
under the normal condition. For example, sialoadhesin (siglec-1), a SA binding receptor
uniquely expressed by macrophage subsets, selectively binds to only α-2,3 linked SAs [12].
While α-2,6 linked SAs may be associated with the cell-cell interaction and signaling
transduction in response to external stimuli. The expression level of SAs on the cell surface
is affected by its biosynthetic pathway. In particular, the synthetic enzyme,
sialyltransferase, functions for adding SAs to the termini of N-linked or O-linked glycans
on the cell surfaces [35]. In our study, western blot showed dramatically change of
ST6GalNAc-II which may be the major contributor for the increase of cell surface α-2,6
linked SAs.
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It is known that glycosylation pattern, including sialylation, changes when cells
undergo apoptosis [16, 19, 20, 36-38]. The extensive studies related to SAs expression
level and cell apoptosis have been done by Dr. Susan L. Bellis research group focusing on
the ST6Gal-I sialyltransferase [20, 39-41]. The decrease of SA level regulated by ST6GalI on TNFR1 Death Receptor has been reported to induce macrophages apoptosis [20].
ST6Gal-I regulated sialylation of β1 integrins can block cell adhesion to galectin-3 and
protect cells against galectin-3 induced apoptosis [40]. Moreover, Fas mediated apoptosis
in colon carcinoma cells can be diminished by sialylation of the Fas death receptor by
ST6Gal-I [39]. One explanation of ST6Gal-I protecting cell against apoptosis can be
explained by its inhibition of galectins blinding to underling galactose, which is reported
to limit the life span of variety of cells [41]. In our study, the ST6Gal-I was found to
decrease significantly after cell treated with atorvastatin, and meantime the cell apoptosis
level elevated dramatically. Based on Dr. Bellis report, the reduction of ST6Gal-I level can
partially contribute to atorvastatin induced macrophage apoptosis. Conversely, an increase
of α-2,6 linked SAs was observed in the late apoptotic lymphocytes [19]. One explanation
for this phenomenon was the redistribution of immature (intracellular) membranes onto the
cell surface during cell apoptosis [19]. This scenario is supported by an earlier study, which
demonstrated the exposure of ER resident proteins and sugars predominantly on the
incompletely processed proteins in ER and Glgi [42]. In our study, we found that α-2,6
linked SAs increased apparently on macrophage cell surface upon atorvastatin activation.
The late apoptotic redistribution of the intracellular membrane may, at least in part, explain
the increase of α-2,6 linked SAs on the cell surface upon atorvastatin stimulation. A further
study to reveal the particular molecular mechanism is highly warranted.
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Most studies on the sialylation status have been limited to SAs on the cell surface
with the methods such as lectins labeling, metabolic labeling, and chemical modification
[43]. Free SAs and conjugated SAs levels in the cell culture medium may change upon cell
activation, such as releasing SAs from cells (surface). In addition, SAs biosynthesis may
increase inside of the cells as well. Therefore, we quantitatively examined the free SAs and
conjugated SAs level in the cell culture medium after atorvastatin treatment, which
indicated SAs releasing fact related to cell function alteration. In addition, we quantified
the total SAs in the cells as well.
So far, few studies tried to quantify the SAs trimmed off from cell surfaces [6, 44].
However, the quantification methods used were often with complicated sample preparation
procedures, such as enzymatic or acid digestion, sample concentration, and SA
derivatization. The DMB derivatization was mainly used for the quantification of SAs [4448]. However, the derivatization involves both high temperature and acidic conditions,
which can hydrolyze part of the conjugated SAs, and severely interrupt the quantitative
accuracy of a small amount of free SAs in the cell culture medium. In our study, we
developed a new LC-MS/MS method for direct quantification of SAs in the cell culture
system. In this method, the free SAs in the medium can be directly analyzed after simple
centrifugation, and no any sample purification or concentration step is needed. Conjugated
SAs in the medium or cell lysate were efficiently hydrolyzed with 2 M acetic acid at 80 oC
for 90 min (data is not shown) followed by direct LC-MS/MS analysis. As a result, there
were no significant changes for free SAs and conjugated SAs in the medium after
atorvastatin treatment, indicating that no apparent sialidases activity changed during this
process. However, the amount of total cellular SAs increased from 369 ± 29 ng/mL to 1080
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± 50 ng/mL upon cell activation. Both confocal microscope and flow cytometry studies
above revealed increasing α-2,6 linked SAs on the cells, indicating that the α-2,6 linked
SAs was the major contributor for the total cellular SAs increase. Our western blot analysis
of sialyltrasferases showed high level of ST6GalNAc-II, indicating it may be the major
contributor for the increase of α-2,6 linked SAs. Overall, the newly developed LC-MS/MS
method was successfully applied to sensitively quantify both free and total SAs in the
culture medium and cell lysate.
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3.5

Conclusion
We profiled SAs dynamics in the whole culture system in the normal and

atorvastatin treated conditions. α-2,3 Linked SAs were found predominant on the cell
surface of Raw 264.7 cells under the normal condition and unchanged upon atorvastatin
treated. In comparison, α-2,6 linked SAs were obscure but increased dramatically on the
cell surface after atorvastatin treatment. In addition, the total SAs of the cells were
significantly increased, while the SAs in the cell culture medium were unchanged after cell
treated with atorvastatin. This is the first time of comprehensively analysis of cell surface
SAs of their levels and linkages, free, conjugated and total SAs in the culture medium, and
total SAs in the cells by combination of confocal microscopy, flow cytometry, and LCMS/MS, which provide a sensitive, specific and systematic way to globally study SAs in
the cell culture system. This work will contribute to a better understanding of the
physiological and pathological roles of SAs in macrophages and the immune system as
well. In general, the reported methods can be expanded to study SAs status of any kind of
cells of interests.

124

3.6

Reference

1.

Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW,
Etzler ME. 2009. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY):
Cold Spring Harbor Laboratory Press.

2.

Angata T, Varki A. 2002. Chemical diversity in the SAs and related alpha-keto
acids: an evolutionary perspective. Chem Rev. 102: 439-469.

3.

Schauer R. 2000. Achievements and challenges of SA research. Glycoconj J. 17:
485-499.

4.

Varki NM, Varki A. 2007. Diversity in cell surface SA presentations: implications
for biology and disease. Lab Invest. 87: 851-857.

5.

Crocker PR, Gordon S. 1986. Properties and distribution of a lectin-like
hemagglutinin differentially expressed by murine stromal tissue macrophages. J
Exp Med. 164: 1862-1875.

6.

Gorczyca W, Wieczorek Z, Lisowski J. 1989. Cell surface SA affects
immunoglobulin binding to macrophages. FEBS Lett. 259: 99-102.

7.

Cowing C, Chapdelaine JM. 1983. T cells discriminate between Ia antigens
expressed on allogeneic accessory cells and B cells: a potential function for
carbohydrate side chains on Ia molecules. Proc Natl Acad Sci U S A. 80: 60006004.

8.

Frohman M, Cowing C. 1985. Presentation of antigen by B cells: functional
dependence on radiation dose, interleukins, cellular activation, and differential
glycosylation. J Immunol. 134: 2269-2275.
125

9.

Bagriaçik EU, Miller KS. 1999. Cell surface SA and the regulation of immune cell
interactions: the neuraminidase effect reconsidered. Glycobiology. 9: 267-275.

10.

Crocker PR, Mucklow S, Bouckson V, McWilliam A, Willis AC, Gordon S, Milon
G, Kelm S, Bradfield P. 1994. Sialoadhesin, a macrophage SA binding receptor for
haemopoietic cells with 17 immunoglobulin-like domains. EMBO J. 13: 44904503.

11.

11. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. 2001.
Characterization of human sialoadhesin, a SA binding receptor expressed by
resident and inflammatory macrophage populations. Blood. 97: 288-296.

12.

Varki A, Angata T. 2006. Siglecs-the major subfamily of I-type lectins.
Glycobiology. 16: 1R-27R.

13.

Stamenkovic I, Seed B. 1990. The B-cell antigen CD22 mediates monocyte and
erythrocyte adhesion. Nature. 345: 74-77.

14.

Simmons D, Seed B. 1988. Isolation of a cDNA encoding CD33, a differentiation
antigen of myeloid progenitor cells. J Immunol. 141: 2797-2800.

15.

Arquint M, Roder J, Chia LS, Down J, Wilkinson D, Bayley H, Braun P, Dunn R.
1987. Molecular cloning and primary structure of myelin-associated glycoprotein.
Proc Natl Acad Sci U S A. 84: 600-604.

16.

Rapoport E, Pendu JL. 1999. Glycosylation alterations of cells in late phase
apoptosis from colon carcinomas. Glycobiology. 9: 1337-1345.

17.

Morris RG, Hargreaves AD, Duvall E, Wyllie AH. 1984. Hormone-induced cell
death. 2. Surface changes in thymocytes undergoing apoptosis. Am J Pathol. 115:
426-436.

126

18.

Peter ME, Hellbardt S, Schwartz-Albiez R, Westendorp MO, Walczak H,
Moldenhauer G, Grell M, Krammer PH. 1995. Cell surface sialylation plays a role
in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death
Differ. 2: 163-171.

19.

19. Meesmann HM, Fehr EM, Kierschke S, Herrmann M, Bilyy R, Heyder P, Blank
N, Krienke S, Lorenz HM, Schiller M. 2010. Decrease of SA residues as an eat-me
signal on the surface of apoptotic lymphocytes. J Cell Sci. 123: 3347-3356.

20.

20. Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC, Bellis SL. 2011.
ST6Gal-I regulates macrophage apoptosis via α2-6 sialylation of the TNFR1 death
receptor. J Biol Chem. 286: 39654-39662.

21.

Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi
M, Schoen FJ, Libby P. 2001. An HMG-CoA reductase inhibitor, cerivastatin,
suppresses growth of macrophages expressing matrix metalloproteinases and tissue
factor in vivo and in vitro. Circulation. 103: 276-283.

22.

Croons V, De Meyer I, Houten SM, Martinet W, Bult H, Herman AG, De Meyer
GR. 2010. Effect of statins on the viability of macrophages and smooth muscle
cells. J Cardiovasc Pharmacol. 55: 269-275.

23.

Liang SL, Liu H, Zhou A. 2006. Lovastatin-induced apoptosis in macrophages
through the Rac1/Cdc42/JNK pathway. J Immunol. 177: 651-656.

24.

Pahan K, Sheikh FG, Namboodiri AM, Singh I. 1997. Lovastatin and phenylacetate
inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes,
microglia, and macrophages. J Clin Invest. 100: 2671-2679.
127

25.

Huang KC, Chen CW, Chen JC, Lin WW. 2003. HMG-CoA reductase inhibitors
inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed
Sci. 10: 396-405.

26.

Matsumoto M, Einhaus D, Gold ES, Aderem A. 2004. Simvastatin augments
lipopolysaccharide-induced proinflammatory responses in macrophages by
differential regulation of the c-Fos and c-Jun transcription factors. J Immunol. 172:
7377-7384.

27.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M,
Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. 2002. The HMG-CoA reductase
inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous
system autoimmune disease. Nature. 420: 78-84.

28.

Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 21: 1712-1719.

29.

Lehmann F, Tiralongo E, Tiralongo J. 2006. SA-specific lectins: occurrence,
specificity and function. Cell Mol Life Sci. 63: 1331-1354.

30.

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers
MH. 1994. Annexin V for flow cytometric detection of phosphatidylserine
expression on B cells undergoing apoptosis. Blood. 84: 1415-1420.

31.

Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. 1995. A novel assay
for apoptosis. Flow cytometric detection of phosphatidylserine expression on early
apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184: 3951.
128

32.

Takashima S. 2008. Characterization of mouse sialyltransferase genes: their
evolution and diversity. Biosci Biotechnol Biochem. 72: 1155-1167.

33.

Videira PA, Amado IF, Crespo HJ, Algueró MC, Dall'Olio F, Cabral MG, Trindade
H. 2008. Surface alpha 2-3- and alpha 2-6-sialylation of human monocytes and
derived dendritic cells and its influence on endocytosis. Glycoconj J. 25: 259-268.

34.

Crespo HJ, Lau JT, Videira PA. 2013. Dendritic cells: a spot on sialic Acid. Front
Immunol. 4: 491

35.

Dall’Olio F. 2000. The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and
functional role. Glycoconj J. 17: 669–676.

36.

Bilyy RO, Antonyuk VO, Stoika RS. 2004. Cytochemical study of role of alpha-dmannose- and beta-d-galactose-containing glycoproteins in apoptosis. J Mol Histol.
35: 829-838.

37.

Franz S, Frey B, Sheriff A, Gaipl US, Beer A, Voll RE, Kalden JR, Herrmann M.
2006. Lectins detect changes of the glycosylation status of plasma membrane
constituents during late apoptosis. Cytometry A. 69: 230-239.

38.

Heyder P, Gaipl US, Beyer TD, Voll RE, Kern PM, Stach C, Kalden JR, Herrmann
M. 2003. Early detection of apoptosis by staining of acid-treated apoptotic cells
with FITC-labeled lectin from Narcissus pseudonarcissus. Cytometry A. 55: 86-93.

39.

Swindall AF, Bellis SL. 2011. Sialylation of the Fas death receptor by ST6Gal-I
provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol
Chem. 286: 22982-22990.

129

40.

Zhuo Y, Chammas R, Bellis SL. 2008. Sialylation of beta1 integrins blocks cell
adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J
Biol Chem. 283: 22177-22185.

41.

Zhuo Y, Bellis SL. 2011. Emerging role of alpha2,6-sialic acid as a negative
regulator of galectin binding and function. J Biol Chem. 286: 5935-5941.

42.

Franz S, Herrmann K, Fürnrohr BG, Sheriff A, Frey B, Gaipl US, Voll RE, Kalden
JR, Jäck HM, Herrmann M. 2007. After shrinkage apoptotic cells expose internal
membrane-derived epitopes on their plasma membranes. Cell Death Differ. 14:
733-742.

43.

Chen X, Varki A. 2010. Advances in the biology and chemistry of SAs. ACS Chem
Biol. 5: 163-176.

44.

Eguchi H, Ikeda Y, Ookawara T, Koyota S, Fujiwara N, Honke K, Wang PG,
Taniguchi N, Suzuki K. 2005. Modification of oligosaccharides by reactive oxygen
species decreases sialyl lewis x-mediated cell adhesion. Glycobiology. 15: 10941101.

45.

Hara S, Yamaguchi M, Takemori Y, Furuhata K, Ogura H, Nakamura M. 1989.
Determination of mono-O-acetylated N-acetylneuraminic acids in human and rat
sera by fluorometric high-performance liquid chromatography. Anal Biochem. 179:
162-166.

46.

Morimoto N, Nakano M, Kinoshita M, Kawabata A, Morita M, Oda Y, Kuroda R,
Kakehi K. 2001. Specific distribution of SAs in animal tissues as examined by LCESI-MS after derivatization with 1,2-diamino-4,5-methylenedioxybenzene. Anal
Chem. 73: 5422-5428.

130

47.

Galuska SP, Geyer H, Mink W, Kaese P, Kühnhardt S, Schäfer B, Mühlenhoff M,
Freiberger F, Gerardy-Schahn R, Geyer R. 2012. Glycomic strategy for efficient
linkage analysis of di-, oligo- and polySAs. J Proteomics. 75: 5266-5278.

48.

Bayer NB, Schubert U, Sentürk Z, Rudloff S, Frank S, Hausmann H, Geyer H,
Geyer R, Preissner KT, Galuska SP. 2013. Artificial and natural SA precursors
influence the angiogenic capacity of human umbilical vein endothelial cells.
Molecules. 18: 2571-2586.

131

CHAPTER IV

SIALYLATION AND DESIALYLATION DYNAMICS OF
MONOCYTES UPON DIFFERENTIATION AND POLARIZATION
TO MACROPHAGES

4.1

Introduction
Macrophages display remarkable plasticity that allows them to acquire functionally

distinct phenotypes and take part in a large number of physiological and pathological
processes [1]. Monocytes are precursors for tissue macrophages, in replenishing resident
macrophages under normal states and in response to inflammation signals by quickly
moving to the sites of infection and dividing/differentiating to macrophages in the tissues.
Further, macrophages can be phenotypically polarized to classically (M1) or alternatively
(M2) activated cells, both of them represent phenotypic extremes of macrophage
differentiation [2,3]. These cells are often characterized by the expression of their specific
cell surface protein markers, secreted cytokines and
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chemokines, and transcription and epigenetic pathway. However, the precisely molecular
determinants in mediating macrophage phenotypic heterogeneity and functional plasticity
are still largely unknown.
A density layer of glycans is expressed on the macrophage cell surface. Lines of
evidence have hinted to potential roles of cell-surface glycans in the functions of
macrophages [4]. SAs are a family of 9-carbon containing acidic monosaccharides and
often terminate cell surface glycans of either glycoproteins or glycolipids. The C-5-amino
derivative represents the well-known neuraminic acid, and its amino functional group can
be either acetylated (N-acetylneuraminic acid, Neu5Ac) or glycolylated (Nglycolylneuraminic acid, Neu5Gc). The most abundant SA is Neu5Ac. They exist on either
N- or O-linked glycans, being attached to either Gal, or GalNAc units via α-2,3 or α-2,6
linkage, which are synthesized by specific enzymes [5]. Accumulated evidences indicated
that cell surface SAs can dramatically impact cell properties and represent different cellular
statuses [6]. Therefore, the expression levels and linkages of SAs, named as sialylation
status, may be biomarkers of specific cell status/population of macrophages and may be
directly involved in macrophages functions as well.
The linkage and expression level of cell surface SA are controlled by both the
sialylation pathway catalyzed by specific sialyltransferse enzymes and the desialylation
process catalyzed by specific sialidase enzymes and environment cues. In this study, we
systematically investigated the sialylation and desialylation profiles of human monocytic
leukemia cell line THP-1 after differentiation to M0 macrophages and polarization to M1,
and M2 macrophages (Figure 20). THP-1 monocytes were induced with phorbol 12myristate 13-acetate (PMA) to differentiate into macrophages (M0), and further polarized
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with LPS and IFN-γ to generate M1 macrophages, with IL4 and IL13 to generate M2
macrophages [7,8]. Cell surface SA reflecting both sialyltrasferase and sialidase activities
was examined by flow cytometry with specific lectins, MAA and SNA. Further, the
siaoglycoconjugates synthesized inside the cells were selectively labeled with the FITClabeled lectins and imaged by confocal microscopy. Moreover, the expression level of
sialyltransferases related to the sialylation status of the cells was confirmed by western
blot, and the SA amount inside the cell was determined by LC-MS/MS. On the other hand,
the desialylation level of the cells was examined by measuring free SA released in the
media and the sialidase activity with the exogenous substrates. Overall, profiling
macrophage cell surface sialylation and desialylation status will contribute to delineate
macrophage diversity and define their phenotypes and functions.
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Figure 20:

Systematically investigation the sialylation and desialylation profiles of

human monocytic leukemia cell line THP-1 after differentiation to M0 macrophages and
polarization to M1 and M2 macrophages.

135

4.2

Materials and methods

4.2.1

Materials
N-Acetyl-D-neuraminic acid (SA, 98%) was supplied by Rose Scientific Ltd.

(Edmonton AB, Canada). N-Acetyl-D-neuraminic acid-1,2,3-13C3 (13C3-SA, 99%),
phorbol 12-myristate 13-acetate (PMA), lipopolysaccharides from Escherichia coli (LPS),
4',6-diamidino-2-phenylindole (DAPI), propidium iodide (PI), RIPA buffer, protease
inhibitor cocktail, rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody,
rabbit anti-ST6GalNAc-VI antibody, rabbit anti-ST3Gal-IV antibody, rabbit anti-ST3GalVI antibody, and goat anti-rabbit IgG-peroxidase antibody were purchased from SigmaAldrich Inc. (St. Louis, MO, USA). Rabbit anti-ST3Gal-I antibody and rabbit anti-ST3GalV antibody were from Fisher Scientific (Hanover park, IL, USA). Rabbit anti-Human
recombinant IFN-γ, IL-4 and IL-13, and FITC labeled mouse anti-human CD11b antibody
were obtained from Life Technologies (Grand Island, NY, USA). FITC labeled MAA
lectin was from bioWORLD (Dublin, OH, USA). FITC labeled SNA lectin was provided
by Vector Laboratories (Burlingame, CA, USA). 4-Methylumbelliferyl N-acetyl-α-Dneuraminic acid (4-MU-NANA) sodium salt was purchased from Carbosynth LLC (San
Diego, CA, USA). GM3 ganglioside was obtained from Avanti Polar Lipids (Alabaster,
AL, USA). Cytokine analysis was performed by EVE technologies (Calgary, Alberta,
Canada).
4.2.2

Cell differentiation and polarization
THP-1 monocytes, obtained from American Type Culture Collection, were

cultured in RPMI-1640 medium (Cleveland Clinic Core Facility, Cleveland, OH, USA)
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supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, NY, USA)
and 1% penicillin/streptomycin (Cleveland Clinic Core Facility, Cleveland, OH, USA) in
a humidified atmosphere containing 5% CO2 at 37 oC. The differentiation of THP-1
monocytes to macrophages was accomplished by PMA stimulation for 48h. To generate
M1-polarized macrophages, LPS (100 ng/mL) and IFN-γ (20 ng/mL) were added at the
last 18 h of PMA treatment. To generate M2-polarizedmacrophages, IL4 (20 ng/mL) and
IL13 (20 ng/mL) were added at the last 18 h of PMA treatment [7, 8]. In order to quantify
SA in the medium, FBS was removed from culture medium before the addition of PMA.
4.2.3

Flow cytometric analysis
To determine cell surface SAs, cells were washed with cold PBS, and then

incubated with 50 μL of FITC labeled MAA (10 μg/mL) or SNA (5μg/mL) for 15 min at
room temperature in dark. Cells were subsequently washed, re-suspended in cold PBS and
analysed by a FACSCantoⅡ flow cytometer operated through BD FACSDiva software
(BD Bioscience, Mountain View, CA, USA). For the CD11b staining, cells were washed,
suspended in cold FACS buffer (PBS, 0.5% BSA, and 0.1% sodium azide), and blocked
with 10% heat inactivated human serum for 20 min on ice. Cells were then centrifuged and
suspended in 100 μL cold FACS buffer with 5 μL FITC labeled CD11b antibody. After 30
min incubation on ice, cells were washed and re-suspended in cold FACS buffer for flow
analysis.
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4.2.4

Confocal microscopy
THP-1 monocytes were seeded on cover slips in 6-well plate at a density of one

million cells/well, and then differentiated and polarized to different type of macrophages
following the method described in the Cell Differentiation and Polarization section. To
determine SA expression of the macrophages, cells were washed with cold PBS, and fixed
with 4% PFA for 10 min. Excess PFA was removed, and optionally the cells were
permeabilized with 0.2% TritonX-100 for 10 minutes to expose SAs inside the cells. Then
cells were stained with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL) for 15 min,
followed by 2 min DAPI stain. Unbound lectin and DAPI were washed off with PBS, and
cover slips were mounted on ProLong Gold Antifade reagent. Images were acquired at a
60 × magnification using a Nikon A1Rsi confocal microscope, and data analysis was
performed using NIS-Elements software (Nikon Instruments Inc., Melville, NY, USA). To
determine SAs expressed on THP-1 monocytes, the cover slips placed in 6-well plate were
first treated with 1% alcian blue solution (Electron Microscopy Sciences, Hatfield, PA,
USA) for 30 min, and then one million of cells in PBS buffer were seeded in each well.
After standing for 20 min, the cells deposited on cover slips were fixed with 4% PFA and
then followed the steps for macrophages staining.
4.2.5

LC-MS/MS analysis
SAs in the media and cell lysates were quantified according to our established

protocol [9]. Briefly, the chromatography was performed on a Nexera liquid
chromatography system (Shimadzu, Columbia, MD, USA). The separation of SA and 13C3SA (internal standard, IS) was carried out by a Primesep D column (2.1 x 100mm, 5 μm;
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SIELC Technologies, Prospect Heights, IL, USA) in a binary gradient mode with phase A
containing 10 mM ammonium formate and 0.1% formic acid in water, and phase B
composed of 90% acetonitrile, 10% water, 3 mM ammonium formate, and 0.04% formic
acid. The gradient elution started at 10% phase B and changed linearly to 100% B from 1.1
min to 4.0 min. To equilibrate the column, the gradient sharply dropped to 10% B from 6.0
min to 6.1 min and maintained for 3 min. The MS detection was carried out by a Qtrap
5500 mass spectrometer equipped with eletrospray ionization source (AB SCIEX,
Framingham, MA, USA). The quantitative transitions were set at m/z 308 → 87 for SA,
and 311 → 90 for IS. The data acquisition and processing were conducted using Analysis
1.6.1 software. The calibration range for SA was from 2.00 to 1.00×10 3 ng/mL.
To quantify free SA in the medium, 95 μL of culture medium was spiked with 5 μL
of IS, and then 5 μL of the mixture was subjected to LC-MS/MS analysis. The total SA in
culture medium was determined by hydrolyzing the sample with 2 M acetic acid (1:1) at
80 oC for 90 min, and then mixing 95 μL of the lysate with 5 μL of the IS before analysis.
For quantification of cell lysate SA, the sample at a density of 1×10 6 cells/mL was
untrosonicated to obtain homogeneous mixture and then followed the procedure of total
SA quantification for culture medium.
4.2.6

Sialidase activity measurement
Cells in the indicated conditions were collected and two millions of the cells were

suspended in the reaction buffer, which containing 0.05 M sodium acetate at pH 4.4, 0.1%
Triton X-100, and 0.1% BSA. The activity of NEU1 and NEU3 were determined by the
addition of 0.125 mM 4-MU-NANA and 0.250 mM ganglioside GM3, respectively [10139

12]. After1 h incubation at 37 oC, the reaction mixtures were centrifuged to remove cellular
debris, and the supernatants were precipitated with acetonitrile at 1:3 ratio to remove the
soluble proteins. Then 20 μL of the supernatant was mixed with 5 μL of IS and 75 μL of
PBS, and 5 μL of the mixture was subjected to the LC-MS/MS analysis. Protein
concentrations in each assay were measured by the Bradford method using a protein assay
kit (Bio-Rad, Hercules, CA, USA). One unit of sialidase activity was defined as one nmol
of free SA that released from one mg of total protein per hour at 37 oC.
4.2.7

Western blot
Cells in the indicated conditions were lysed with a mixture of RIPA buffer and

protease inhibitor cocktail (1:100, v/v) on ice for 5 min, and the cell lysates were collected
and clarified by centrifugation at 15,000 g at 4 oC for 10 min. Protein concentrations were
measured by Bradford method using a protein assay kit. Proteins at amount of 30 μg/sample
were separated on SDS-12% polyacrylamide gels and then transferred to polyvinylidene
difluoride membrane. The membranes were blocked with 5% nonfat milk for 1 h at room
temperature, followed by incubation with primary antibodies at 4oC overnight. After
washing with tri-buffered saline containing 0.05% Tween 20 (TBS-T) buffer, the
membrane was probed with specific secondary antibodies conjugated with horseradish
peroxidase for 1 h at room temperature. Protein detection was accomplished by using the
ECL Prime kit (Pierce) with the LI-COR Odyssey Fc imaging system.
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4.3

Results

4.3.1

Cell surface SA analyzed by flow cytometry
To determine the cell surface sialylation level during THP-1 monocytes

differentiation, cells were incubated with PMA at 10, 20, and 50 ng/mL for 48 h. The
differentiation of THP-1 monocytes to macrophages was confirmed by the expression of
CD11b, which showed more than 80% positive after 48 h treatment with PMA (data is not
shown) [13, 14]. SA on the cell surface is found most commonly linked to underlying
sugars with α-2,3 and α-2,6 linkages [15]. To examine the cell surface sialylation status,
we performed flow cytometry to distinctively measure SA with different linkages on the
THP-1 monocytes and macrophages by using MAA-FITC and SNA-FITC labeling, which
selectively recognize α-2,3 and α-2,6 linked SA, respectively. As observed from Figure 21
A and B, both MAA and SNA peaks left shifted after cells treated with PMA, suggesting
the decrease of both α-2,3 and α-2,6 linked SA on the cell surface of the differentiated
macrophages. The statistical analysis showed the mean fluorescent intensity (MFI) of
MAA labeled α-2,3 SA decreased more than 20% and SNA labeled α-2,6 SA decreased
more than 30% (Figure 21 C). The change of cell surface SA was not related to PMA
concentration as observed in Figure 21 C.
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Figure 21:

Cell surface SAs determined by flow cytometry. (A): THP-1 monocytes

were labeled with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL). (B): M0 macrophages
were obtained by differentiation of THP-1 monocytes with PMA at 10 ng/mL for 48 h, and
then the cells were labeled with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL). (C):
Statistical analysis of three independent experiments (n=3). Significantly different values
(*P < 0.05, **P < 0.01) were obtained by SPSS 19.0 with paired-samples t test.
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Next, the polarization of M0 macrophages was carried out by the stimulation with
M1 cytokines (LPS and IFN-γ) or M2 cytokines (IL-4 and IL-13) with PMA at
concentrations of 10, 20, and 50 ng/mL, respectively. Cytokines including GM-CSF, IL1β, IL-6, IL-12, and TNFα were analyzed before and after polarization (Figure 22). The
change of cell surface SA was examined by flow cytometry by using MAA-FITC and
SNA-FITC labeling too. As a result, no significant peak shift was observed for either MAA
or SNA labeling compared to M0 macrophages (data is not shown), suggesting the cell
surface SA content was unchanged, which may be not crucial during the macrophage
activation. The sialidase from Arthrobacter ureafaciens was used to release cell surface
SA from M0, M1 and M2 macrophages. However, due to the insufficient releasing of α2,6linked SA in the neutral pH, no further study was performed with exogenous sialidase
(Figure 23).
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Figure 22:

Cytokine analysis of THP-1 derived M0, M1 and M2 macrophages (n=3). THP-1 monocytes were seeded in 12-well

plate at a density of 0.5 million cells per well. After differentiation with PMA at 10 ng/ml and polarization with M1 and M2 cytokines,
GM-CSF, IL-1β, IL-6, IL-12, and TNFα in the medium were quantified with human cytokine array offered by EVE technologies. As a
result, M1 has higher concentrations in IL-1β, IL-6, IL-12, and TNFα compared to M0 and M2. While M0 and M2 show similar cytokine
profile, except granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a specific marker for M1.
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Figure 23:

Cell surface SA profile after sialidase treatment. THP-1 derived M0, M1

and M2 macrophages were incubated with sialidase from Arthrobacter ureafaciens in PBS
buffer for 1h. Then α2,3-linked SA was labeled with MAA-FITC (10 μg/mL), and α2,6linked SA was labeled with SNA-FITC (5 μg/mL). The nuclei were stained with DAPI (1
μg/mL). As is observed, α2,3-linked SA is more prone to sialidase treatment, while α2,6linked SA shows a less releasing efficiency.
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4.3.2

Cellular SA expression determined by confocal microscopy
To visualize the SA expression, the cells were permeablized to detect SA inside the

cells and without permeabilization to determine the cell surface SA only. As shown in
Figure 24 B and D, both MAA labeled α 2,3-linked SA and SNA labeled α2,6-linked SA
were found highly expressed inside the cells after PMA treatment for 48 h, indicating that
the sialylation became more active in the differentiated macrophages, and this change was
not related to PMA concentrations (data is not shown). However, all the M0, M1, and M2
macrophages showed a similar expression level of SA inside the cells. We were not able
to determine any difference in fluorescent intensity of cell surface SA between monocytes
and M0, M1, and M2 macrophages (Figure 24 A and C).
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Figure 24:

The SA expression level examined by confocal microscopy. The

differentiation of THP-1 monocytes was carried out by incubation with 10 ng/mL of PMA
for 48 h. M1 and M2 polarizing cytokines were added at the last 18 h of PMA
differentiation. Cells in (B) and (D) groups were permeabilized with Triton X-100 prior to
MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL) stain. (A): α2,3-linked SA on the cell
surfaces was labeled with MAA-FITC. (B): Cells were permeablized first, and then α2,3147

linked SA on the cell surfaces and inside the cells was labeled with MAA-FITC. (C): α2,6linked SA on the cell surfaces was labeled with SNA-FITC. (D): Cells were permeablized
first, and then α2,6-linked SA on the cell surfaces and inside the cells was labeled with
SNA-FITC. The results were reproduced at least in three independent experiments. The
scale bar represents 10 μm.
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4.3.3

LC-MS/MS quantification of SA in the culture media and cell lysates
The SA concentrations in the culture media and cell lysates were measured by LC-

MS/MS. The results are listed in Figure 25, which shows the dramatic increase of SA in
the cell culture media and cell lysates with PMA treatment in 48 h. For example, after cells
incubated with 10 ng/mL PMA for 48 h, the free SA in the medium reached to 12.83 ± 0.70
ng/mL compared with 4.18 ± 0.05 ng/mL in non-differentiated cells; the total SA in the
medium increased in a similar manner, which changed from 28.13 ± 1.36 ng/mL to 73.50
± 2.55 ng/mL. The SA in the cell lysate at a density of 1 × 106 cells/mL was found to be
728 ± 17 ng/mL in the monocytes and increased to 1310 ± 203 ng/mL in the differentiated
macrophages. However, the concentration of PMA did not show any significant effect on
the SA concentration in either culture media or cell lysates.
Upon polarization of M0 macrophages with M1 and M2 cytokines, no significant
change of SA in the medium was found (Figure 25 D and E). While SA in the cell lysates
changed depending on the initial PMA concentration used to differentiate monocytes. The
SA concentration in M1 macrophages decreased significantly compared with M0
macrophages at the PMA concentration of 50 ng/mL while the SA amount increased in the
M2 macrophages, and the significant difference was found at PMA concentrations of 20
and 50 ng/mL.
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Figure 25:

SA levels in the cell culture media and cell lysates determined by LC-

MS/MS. Free SA in the media was determined by LC-MS/MS directly. The medium
samples were hydrolyzed with acetic acid prior to LC-MS/MS analysis to quantify the total
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SA.

For cell lysate SA quantification, cells were ultrasonicated first to obtain

homogeneous mixture, and then followed by acid hydrolysis and LC-MS/MS analysis. (A):
Free SA in the PMA differentiated macrophages (M0) culture media. Cells were cultured
at a density of 1 million cells/2 ml medium and treated with vehicle (concentration 0
ng/mL) or PMA at concentrations of 5, 10, 20, 50, 100 ng/mL. The media were collected
at 24, 48, and 72h for LC-MS/MS analysis. (B): Total SA in the M0 macrophages culture
media. (C): The SA in the M0 cell lysates. (D): Free SA in the M0, M1 and M2
macrophages culture media. Cells were incubated with PMA at concentrations of 10, 20,
and 50 ng/mL for 48 h. The M1 and M2 polarizing cytokines were added in the last 18 h
of PMA differentiation. (E): Total SA in the M0, M1 and M2 macrophages culture media.
(F): The SA in the M0, M1, and M2 cell lysates. The results were repeated in at least three
independent experiments. Data is a representive from one experiment with three samples
(n=3). The statistical analysis was performed using SPSS 19.0 with paired-samples t test.
*P < 0.05, **P < 0.01.
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4.3.4

Sialidases activity assay
During the differentiation of THP-1 monocytes to macrophages, free SA in the

culture medium increased in all three conditions after 48 h treatment, which was
corresponded with the decease of SA on the cell surface. The decreasing could be attributed
to the elevated desialylation process, which was catalyzed by specific sialidases located in
lysosomal, cytosol and cell surface. It was known that the lysosomal Neu1 and plasma
membrane-associated Neu3 are two major forms of sialidases in mammalian cells [16]. In
this study, the sialidase activity of Neu1 and Neu3 in THP-1 monocytes and M0
macrophages

was

determined

using

the

exogenous

sialidase

substrates

4-

methylumbelliferyl N-acetyl-α-D-neuraminic acid (4-MU-NANA) sodium salt and
ganglioside GM3, respectively [10-12, 17]. For control analysis, the cells were incubated
with only reaction buffer to determine the desialylation level of endogenous
sialylconjugates under the same condition. As shown in Figure 26, both endogenous group
and 4-MU-NANA group indicate the sialidase activity increased significantly after 24 h
differentiation, and the highest activity reached in 48 h. For example, after 48 h
differentiation the sialidase activity increased from 0.97 ± 0.02 units to 5.08 ± 0.03 units
in endogenous group, from 12.01 ± 0.54 units to 28.48 ± 2.28 units in 4-MU-NANA group,
while from 4.17 ± 0.29 units to 5.97 ± 0.38 units in the GM3 group. These data suggest
Neu1 is the major contributor for the sialidase activity during THP-1 monocytes
differentiation. Since no apparent change of free SA in the medium during M1 and M2
macrophages polarization, and thus the sialidase activity was not examined in these
processes.
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Figure 26:

Comparison of sialidase activity in THP-1 monocytes and PMA

differentiated M0 macrophages. The monocytes were differentiated with PMA at 10
ng/mL, and the sialidase activity was measured at 24, 48, and 72 h with 4-MU-NANA and
GM3 as substrates for NEU1 and NEU3, respectively. In the endogenous group, cells were
incubated with only reaction buffer, and the results represented sialidase activity with
endogenous sialylconjugates as substrates. This results were repeated in three independent
experiments. Data is a representative from one experiment with three samples (n=3).
Significantly different values (*P < 0.05, **P < 0.01) were obtained by SPSS 19.0 with
paired-samples t test.
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4.3.5

Sialyltransferase expression level determined by Western blot
The LC-MS/MS results of increased cellular SA were in accordance with the

enhanced sialylation inside the cells as observed by confocal microscopy above. Therefore,
we performed Western Blot assays to distinctively study the effect of sialyltransferases in
THP-1 monocytes and the differentiated and polarized macrophages. Sialyltransferases for
α2,3-linkages, including ST3Gal-I for O-glycan, ST3Gal-IV for both O-glycan and Nglycan, ST3Gal-V for glycolipid, and ST3Gal-VI for N-glycan, were compared. For α2,6linked SA synthesis, sialyltransferases including ST6Gal-I for N-glycan, ST6GalNAc-II
for O-glycan, and ST6GalNAc-VI for glycolipids were investigated. As a result (Figure
27), both ST3Gal-I and ST3Gal-V showed a low expression level in the monocytes, but
increased in the M0, M1 and M2 macrophages. While ST3Gal-IV and ST3Gal-VI were not
detected in all the cells, which may indicate the low abundance of α2,3-sialylated Nglycans in THP-1 cells. In terms of α2,6-linked SA, ST6Gal-I and ST6GalNAc-II increased
the expression in the macrophages compared to the undifferentiated monocytes. However,
the expression of ST6GalNAc-VI decreased dramatically in the macrophages. The
tremendous change of ST3Gal-V and ST6GalNAc-VI suggests the vast reorganization of
sialylated glycolipids during monocytes differentiation and polarization.
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Figure 27:

Western blot analysis of sialyltransferases in THP-1 monocytes and the

derived macrophages. THP-1 monocytes were incubated with 10 ng/mL of PMA for 48 h
to obtain M0 macrophages. The M1 and M2 macrophages were polarized by addition of
the corresponding cytokines in the last 18 h of PMA differentiation. Sialyltransferases
including ST3Gal-I, ST3Gal-V, ST6Gal-I, ST6GalNAc-II, and ST6GalNAc-VI were
determined by western blot using rabbit anti-ST3Gal-I antibody, rabbit anti-ST3Gal-V
antibody, rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody and rabbit
anti-ST6GalNAc-VI antibody, respectively.
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4.4

Discussion
Monocytes originate in the bone marrow and are then released into the peripheral

blood, where they circulate for several days before differentiation to macrophages,
contributing to the host defense and tissue remodeling and repair [18]. SA terminates most
of the glycan structures on the cell surfaces and secreted glycoconjugates. Consequently,
it is involved in variety of physiological and pathological activities of immune cells.
However, so far there is no systematic study related to the sialylation and desialylation
status of monocytes and the corresponding macrophages. In this study, THP-1 monocytes
were used to comprehensively profile the SA level change during monocytes differentiate
to M0 macrophages and further polarize to M1 and M2 macrophages. The cell surface SA
in both α2,3- andα2,6-linkages were decreased during the process, and this result was
further supported by the elevation of cellular Neu1 activity and increase of free SA
concentration in the medium. Next, SA synthesis increased in the macrophages, which was
indicated by confocal images of lectin labeled siaoglycoconjugates inside the cells and the
SA amount inside the cells determined by LC-MS/MS. These findings were further
supported by the change of sialyltransfereses with Western Blot assays which showed the
elevated expression of ST3Gal-I, ST3Gal-V, ST6Gal-I, and ST6GalNAc-II while the down
regulation of ST6GalNAc-VI (Figure 27). It was found that Monocyte-characteristic
surface sialoglycoproteins disappear during in vitro differentiation of monocytes to
adherent macrophages, which was considered to a parameter for the conversion of
monocytes to macrophages [19]. Our flow cytometry results were consistent with this
finding, that showed the decrease of both α2,3- and α2,6-linked SA on the cell surfaces
during THP-1 monocytes differentiate to macrophages.
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A previous study focused on the endogenous sialidases of human monocytes during
differentiation to macrophages show a significant increase of NEU1 and NEU3 as analyzed
by PCR and Western Blot [12]. In our study, we provide the first evidence that the increase
of Neu1 activity is associated with the increase of free SA released in the cell culture
medium. Neu1 catalyzes lysosomal catabolism of sialylated glycoconjugates. During the
differentiation of monocytes or the monocytic cell lines, THP-1, to macrophages, the
majority of Neu1 were translocalized from lysosomes to the cell surface. The suppression
of Neu1 expression in the THP-1 derived macrophages by small interfering RNA or with
anti-Neu1 antibodies was reported significantly reduced the ability of the cells to engulf
bacteria or to produce cytokines [20]. Whereas, treatment of cells with purified Neu1 was
able to reduce surface sialylation and restore the phagocytic ability [21]. However, there is
no difference between medium free SA of M0, M1, and M2 macrophages. This observation
suggests the similarity of sialidase activity between these subtypes of macrophages.
The relative activity of sialyltransferases influences the expression of sialytated
molecules on the cell surfaces and secreted sialoglycoconjugates, and may contribute to
the definition of the glycosylation pattern of monocytes and the corresponding
macrophages. However, no systemic studies have focused on the SA pattern changing
along monocytes differentiation and polarization so far. In our study, the increasing of the
cellular SA level in the differentiated M0 macrophages was confirmed by both LC-MS/MS
and confocal microscopy, while the difference between M0, M1, and M2 macrophages
could be only distinguished by LC-MS/MS on the cellular SA level, which is possibly due
to the sensitivity of the different detection method. The Western Blot results showed
sialyltransferases, including ST6Gal-I, ST6GalNAc-II, ST6GalNAc-VI, ST3Gal-I, and
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ST3Gal-V, contributed to the SA variation in the differentiated and polarized macrophages.
The elevation of ST6Gal-I and ST3Gal-I indicated the enhanced synthesis of α2,6sialylated N-glycans and α2,3-sialylatedO-glycans, respectively. Similar to our
observation, both enzymes were found upregulated during monocytes differentiate to
dendritic cells (DCs) at their mRNA level [22]. ST6GalNAc-II has been reported to be
increased in the LPS treated human macrophages and atorvastatin treated Raw
macrophages, suggesting the increase expression of α2,6-sialylated O-glycans may be
related to cell activation status [9, 23]. ST3Gal-V is responsible for the formation of GM3
using lactosylceramide as the substrate, and previous reports showed the enhancing of
GM3 expression during differentiation of monocytes to macrophages [24, 25], which is in
accordance with the rise of ST3Gal-V in our findings. ST6GalNAc-VI catalyzes the
formation of α2,6-sialyltransferase involved in the synthesis of all α-series gangliosides,
and the decrease of this enzyme level may be related to the well-recognized capability of
macrophages to respond and alter a wide range of lipid products [26]. In our study, both
ST3Gal-IV and ST3Gal-VI that catalyzing the formation of α2,3-linked SA on N-glycans
were undetectable although the mRNA expression was reported in human peripheral blood
monocytes [22]. This observation may result from either the low abundance of α2,3-linked
SA on N-glycans, or the low sensitivity of the corresponding antibodies on the market.
M1 macrophages showed a decreased level of cellular SA, whereas M2
macrophages showed increased in compared to M0 macrophages. This interesting
phenomenon may indicate the cell function change during cell differentiation. M1
macrophages are known to be associated with acute inflammatory responses and M2
macrophages are characterized with inflammatory responses and adaptive type I immunity
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[27-29]. Previous studies indicated that the decrease of sialylation level is always
associated with the increase of inflammatory response and vice versa [20, 21, 30-33]. For
example, the anti-inflammatory activity of immunoglobulin G (IgG) is resulted from the
sialylation of its Fc core polysaccharide, which could be reduced upon the induction of an
antigen-specific immune response. Thus the differential sialylation may provide a switch
from innate anti-inflammatory activity in the steady state to generate adaptive proinflammatory effects upon antigenic challenge [30]. In term of immune cells, the
suppression of Neu1 expression in THP-1 derived macrophages can significantly reduce
the ability of the cells to engulf bacteria or to produce cytokines, while this inflammatory
function can be restored by the treatment of sialidase [20, 21].
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4.5

Conclusion
We report a systematic investigation of sialylation and desialylation dynamics of

monocytes after differentiation and polarization to macrophages. The lectin labeling,
followed with flow cytometry and confocal microscopy detection gives the direct evidence
of SA change regarding to α-2,3 and α-2,6 linkage. Moreover, LC-MS/MS provides a
sensitive and accurate detection of released SAs in both culture medium and SAs
synthesized inside the cells. Further, studies based on the levels of sialidases and
sialyltransferases furnish a fundamental mechanism leading to the alteration of SA, which
could be used to manipulate the differentiation and polarization of monocytes. This work
will contribute to a better understanding of the physiological and pathological roles of SAs
in the monocyte differentiation and polarization as well as the immune system.
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CHAPTER V
SUMMARY

SAs often exist as the terminal sugars of glycan structures of cell surface
glycoproteins and glycolipids. The level and linkages of cell surface SAs, which are
controlled by both sialylation and desialylation processes and environment cues, can
dramatically impact cell functions and represent different cellular statuses. Traditional
approach for SAs study employed the SA binding proteins, lectins, which can specifically
recognize SAs in certain linkages. However, the application of lectins is almost limited to
the intact cells, and the bias in differentiation the change of SAs on the cell surface cannot
be avoid due to the fact that SAs may exist both inside and outside the cell membrance,
and also the spacial hindrance cannot be avoided. SA quantification was used in some
researches to study SA amount change in different conditions. Quinoxilinone
derivatization provides a sensitive and specific way to stuy total SA, as well as SA species.
However, the high temperature and acidic condition make it impossible to analyze only
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the free SA part in matrice, such as cell culture medium and plasma, which contains large
ratio of conjugated SA. Although several direct quatification methods had been developed
for free SA determination, the most sensitive one reported had quantification limit of 100
ng/mL and most of others could only detect SA in μg/ml. These methods may be good for
patient samples with SSDs, which accumulated large amount of free SA, but not applicable
for regular cell culture medium generally with free SA less than 10 ng/mL.
In my study, firstly I developed two new LC-MS/MS methods for broad scope of
SA quantification. The derivatiztion approach using a stable and inexpensive reagent DAT
provides a stable product of SA with high MS response, proving a convenient and costeffective LC-MS/MS analysis of conjugated SA and free SA after protein depletion. In
addition, trace amount of SA in the reagents including water was found in this study, which
made it inaccurate to quantiy low concentration of SA. Therefor, the 13C3-SA was used as
calibration standard to ensure the accuracy of the measurement. Last, this assay used
UHPLC for separation of native/labeled SA and IS from matrix interference, and employed
mass spectrometry in MRM mode for sensitive and selective detection. We have achieved
a LLOQ of 20 ng/mL and a total running time of 4.2 min, which is the most sensitive and
quick measurement for SA with derivatization. This method has been applied to quantify
free SA in plasma samples from cardiovascular disease patients. We have found the
increase of free SA in these patients compared to health individuals. However, more
samples are required to make statistical conclusion.
In order to work on large scale of samples, we further imporved SA quantification
with a non-derivatization method. In this direct LC-MS/MS approach, cell culture medium
can be analyzed directly after simple centrifugation, which provides the most accurate way
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for free SA detection. This method is sensitive enough to quantify SA in 2 ng/mL in culture
medium. However, one limitation for this method is the capability to separate SA
analogues. It affords excellet resolution for Neu5Ac and Neu5Gc, while doesn’t work well
when Neu5Ac loses the first carbon, which is the proposed physiological pathway for
desialylation under oxidative stress; also it shows no retention when the hydroxyl group on
the C-5 in Neu5Gc is substituted with glycine. However, all these problems can be resolved
by DAT derivatization with LC-MS/MS quantification.
LC-MS/MS has been proved to be a powerful tool to quantitatively stuy SA in the
cell lysate, and both free and total SA in the culture medium. With the combination of flow
cytometry and confocal microscopy using fluorescent lectins labeling for the intact cells,
the sialylation status on the cell surface and inside the cells can be reveled, which offers a
powerful approach to comprehensivly study sialylation status in different cellular
conditions related to both physiological and pathological processes. With these approaches,
we performed globally profiling of the sialylation status of macrophages and their release
of SAs in the cell culture medium after atorvastatin treatment. Both flow cytometry and
confocal microscopy results showed that α-2,3 linked SAs were predominant on the cell
surface and changed slightly upon treatment with atorvastatin, while α-2,6 linked SAs were
negligible in the normal culture condition but significantly increased after treatment.
Meanwhile, the amount of total cellular SAs increased about three times upon treatment as
determined by LC-MS/MS method, which further supported the observation from flow
cytometry and confocal microscopy. These results indicated that the cell surface α-2,6
sialylation status of macrophages changes distinctly upon atorvastatin stimulation, which
may reflect on the biological functions of the cells. Moreover, the increase of α-2,6 linked
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SA correlats well with the Annexin V postivie cell ratio, which suggests a possible
correlation of SA and cell apoptosis.
Next, we examined the sialylation and desialylation features during monocytes
differentiate to macrophages. In this study, THP-1 monocytes were used as model cell line
to differentiate to inactivated macropahgs (M0), then polarize to M1 and M2 macrophages
under different stimuli. Interestingly, both α-2,3 and α-2,6 linked SAs on the cell surface
were found to be decreased after monocytes were differentiated to macrophages, which
was in accordance with the increased level of free SA in the cell culture medium and the
elevated activity of endogenous NEU1 sialidase. Meanwhile, the siaoglycoconjugates
inside the cells increased as confirmed by confocal microscopy and the total SA inside the
cells increased as determined by LC-MS/MS. Western blot analysis showed higher
expression levels of sialyltransferases, including ST3Gal-I, ST3Gal-V, ST6Gal-I and
ST6GalNAc-II. Further, upon polarization, the cell surface sialylation levels of M1 and
M2 macrophages remained the same as M0 macrophages, while a slight decrease of
cellular SAs in the M1 macrophages but increase in the M2 macrophages were confirmed
by LC-MS/MS.
In summary, we developed two LC-MS/MS methods for broad scope of SA
quantification. The derivatization method has been successfully applied to determine free
SA in human plasma. The direct quantification approach has been combined with flow
cytometry and confocal microscopy with lectin labeling to profile SAs in the cell culture
system. LC-MS/MS can accurately quantify SA in the cell lysate and culture medium in a
high throughtput fashion. The SA linkages on the cell surface can be distinguished by flow
cytometry and confocal microscopy with specific lectin labelings. The total SA amount in
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the cell lysate provides a direct evidence of the consequence of sialyltransferases change,
and the free SA in the medium can serve as an indicator for sialidases activity.
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CHAPTER VI
FUTURE PERSPECTIVE

6.1

SAs related glycomics study
Glycomic analyses seek to understand how a collection of glycans relates to a

particular biological event. As described before, sialylated glycoconjugates participate in
many biological process, from intracellular signaling to organ development and tumor
growth. However, due to the fact that the understanding of the molecular functions of SAs
in these physiologican and pathological processes are just emerging, it is not surprising that
a clear understanding of the significance of nature’s SAs structural diversity is still missing.
Our current studies have provided the evidence that SA amount and the linkages of the
cells vary under different conditions. To understand the underling molecular mechanism
and reveal new functions of sialylated structure in cell-cell communication, it will be
valube to provide the detail sialylated glycan structure corresponding to different cellular
conditions.
High-resolution mass spectrometry is the primary technique for characterizing the
structures of individual glycans when only small quantities are available, as is the case of
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most glycomic studies. In this typical experiment, the sialylated glycoproteins from cell
lysates can be enriched by lectin affinity column. Then the N-glycans are selectively
released by endoglycosidase such as PNGase F, and the O-glycans are chemically released
by reductive elimination due to no endoglycosidase has been found to work on O-glycan.
The released glycan can be further permethylated to increase the MS response and to
protect the SA structure. Alternatively, the glycans can be analyzed directly under negative
mode or under positive mode after enzymatic desialylation. The detailed glycan sturctures
can be elucidated by the combination of fragmentation pattern and further treatment with
specific glycosidases.
In my study, I have worked with bovine fetutin as a standard glycoprotein, and the
released glycans were analyzed by Bruker Autoflex III MALDI-TOF-TOF mass
spectrometry (Matrix Assisted Laser Desorption/Ionization-Time of Flight). As shown in
Figure 28, this instrument is sensitive to detect glycoproteins on microgram scale with both
native glyans or permethylated glycans. However, no glycans could be identified from the
membrance proteins of THP-1 monocytes, which is likely due to the insufficient sample
amount. In furture, mass spectrometry with higher sensitivity could be utilizd to further
this study.
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Figure 28:

MALDI-TOF-MS spectra of glycans. (A) Permethylated N-glycans from 30

μg fetuin. (B) Desialylated native N-glycans from 30 μg fetuin. (C) A N-glycan sample
released from membrance protein of 10 million THP-1 cells.
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6.2

Systematic and site-specific analysis of sialated proteins on the cell surface of

immune cells
Metabolic oligosaccharide engineering is a methodology that originated over two
decades ago when the sialyltransferases were found to have the capacity to add modified
SAs to glycoconjugates. This technology took a dramatic step forward when the modified
ManNAc analogs were found to be able to incorporate into sialylated glycans. With this
approach, the biorthogonal functional groups such as azide on the ManNAc or Neu5Ac
analogs could be incorparated on the cell surface (Figure 29). Thus this functional group
can further undergo covalent reaction with exogenous agents bearing complementary
functionality which could enable systematic and site-specific analysis of sialated proteins
on the cell surface of immune cells.
The vast remodeling of cell surface sialoglycoproteins in the immune cells under
different activation conditions has been reported in many researches. With the metabolic
oligosaccharide engineering approach, the systematic and site-specific analysis of sialated
proteins on the cell surface can be achieved. Specifically, the unnatural SA containing
bioorthogonal functional group sucha as azide can be incorporated on the cell surface, and
the glycans bearing this special sugar can be tagged by other agents to achieve labeling and
furnish later separation. Then the cells can be lysed, and the labeled glycoconjugates can
be pulled out with specific beads. These purified sialoglycans can be indentified by MS
after PNGase F digestion. Further, if this enzymatic step is carried out in heavy water, all
the Asn is converted to Asp with an

18

O tag that can be identified by MS. Overall, this

combined glycomics and metabolic engineering approach in immune cells has a great
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potential in identifying new targets for disease treatment and vaccine development, and
discovering effective biomarkers for disease detection and surveillance.
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Figure 29:

The principle of the site-specific identification of the cell surface N-

sialoglycoproteome by integrating metabolic labeling and MS-based glycomics
techniques. (Chen W, Smeekens JM, Wu R. 2015. Systematic and site-specific analysis of
N-sialoglycosylated proteins on the cell surface by integrating click chemistry and MSbased proteomics. Chem Sci. 6: 4681-4689.)
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